Medical Imaging Agents Global Market – Forecast To 2028
Chemical substances that improve the visibility of specific organs, tissues, or blood vessels during a diagnostic imaging investigation are known as medical imaging agents which comprise contrast agents and nuclear imaging agents, these agents are administered directly through veins, arteries, and joints or consumed orally. X-ray/computed tomography (CT) imaging exams make use of iodinated and barium-based contrast agents, whereas, Gadolinium-based contrast agents are preferred in MRI (Magnetic Resonance Imaging). These substances improve the reporting or accuracy of how internal structures of the body are working and any associated abnormalities. Ultrasound scans make use of special contrast agents called microbubbles which strongly interact with the ultrasound beam and enhance the details of the heart, liver and kidney. Nuclear medicine is a highly multi-disciplined medical imaging specialty, where, SPECT and PET scanners are used along with small amounts of radioactive material in order to diagnose diseases. According to IQ4I estimates, the Medical imaging agents global market is expected to grow at mid single-digit CAGR from 2021 to 2028 to reach $12,881.0 million by 2028.
Medical imaging agents global market is segmented based on molecule/isotope, modality, application, route of administration, imaging and end-users. The market based on molecule/isotope segmented into contrast agents and nuclear imaging agents, where the contrast agents segment commanded the largest revenue in 2021 and the segment is expected to grow at mid single-digit CAGR from 2021 to 2028. The contrast agents global market is further segmented based on molecule into Iodine based [Ionic (Monomeric and Dimeric), Non-Ionic (Monomeric and Dimeric)], Gadolinium-based contrast agents [Macrocyclic (Ionic and Non-Ionic), Linear (Ionic and Non-Ionic)], microbubble based contrast agent and others which include Barium and iron-based contrast agents. Iodine-based contrast agents market contributed the largest revenue in 2021 and is expected grow at low single-digit CAGR of 4.7% from 2021 to 2028 and the microbubble segment is growing rapidly at late teen double-digit CAGR from 2021 to 2028 due to expansion in disease indications. Based on ionicity, the Iodine-based contrast agent is segmented into ionic and non-ionic. The non-Ionic Iodine-based contrast agents market accounted for the largest share in 2021 and the market is projected to grow at a mid single-digit CAGR from 2021 to 2028. Because of lower osmolality, better tolerance and another advantage, non-ionic iodine contrast agents are preferred and they are less toxic. Ionic Iodine based contrasts are further segmented based on chemical structure into monomers and dimers. Monomers accounted for the largest share in 2021 and is estimated to grow at a mid single-digit CAGR from 2021 to 2028. Non-Ionic as they are safer and tolerable when compared to ionic contrast agents and low osmolar agents do not dissociate into a particle in solution and help in reducing the neurotoxicity. The gadolinium contrast agents are further segmented based on chemical structures into macrocyclic and linear agents, among which the macrocyclic commanded the largest share in 2021 and is expected to grow at high single-digit CAGR from 2021 to 2028. Macrocyclic agents are further segmented into ionic and non-ionic agents, among which, non-ionic commanded the largest revenue in 2021 and is estimated to grow at a mid single-digit CAGR from 2021 to 2028. The Ionic segment is expected to grow at a high single-digit CAGR from 2021 to 2028.
As estimated by IQ4I Research, the nuclear imaging agents global market is poised to grow at mid single-digit CAGR from 2021 to 2028. Increased radioisotopes applications, rise in public awareness, use of SPECT/CT and PET/CT imaging scans, the abundance of radiopharmaceuticals, advancement in imaging technology (hybrid imaging) is boosting nuclear imaging agent's market growth. In addition, increasing need in emerging markets, production of radiopharmaceuticals from cyclotrons, efficient diagnosis and treatments, emerging radio isotopes and replacement of old/traditional equipment are the opportunities likely to propel the growth of the nuclear imaging agents market.
The nuclear imaging agents global market based on isotopes are segmented into Technetium (Tc-99m), Thallium (Tl-201), Gallium (Ga-67), Iodine (I-123), Xe-133, Rhenium (Re-186), Fluorodeoxyglucose (18F-FDG), Gallium (Ga-68), Rubidium (Rb-82) and others. Technetium (Tc-99m) isotope commanded the largest revenue in 2021 and is expected to grow at mid single-digit CAGR from 2021 to 2028 and Gallium (Ga-68) is projected to grow at high double-digit CAGR from 2021 to 2028 due to its increasing use in the diagnosis of neuroendocrine tumors and emerging use in prostate cancer.
The Medical imaging agents market based on modality is segmented into X-ray/CT, MRI, Ultrasound, SPECT and PET. X-Ray/CT market held the largest market revenue in 2021 and is expected to grow at low single-digit CAGR from 2021 to 2028 and the ultrasound segment is growing rapidly at late teen double digit CAGR from 2021 to 2028 due to increased use in diagnostic procedures especially echocardiography, focal liver lesions and ultrasonography of urinary tract.
The Medical imaging agents market based on applications is segmented into cardiovascular, cancer, gastrointestinal, musculoskeletal, neurology, nephrology, obstetrics & gynecology, pulmonary, hepatology and others which include neck, bone and salivary gland imaging. The cardiovascular market accounted for the largest share in 2021 and is expected grow at mid single-digit CAGR from 2021 to 2028 and cancer is the fastest-growing segment with a high single-digit CAGR from 2021 to 2028 due to an increase in cancer imaging such as lung, thyroid and breast cancer imaging procedures using Iodine, Gadolinium and microbubble contrast agents and radiopharmaceuticals.
Medical imaging agents market by route of administration is segmented into intravascular, oral, rectal and others, which include intraosseous, intrathecal and intravesical. Intravascular accounted for the largest share in 2021 and is the fastest-growing market with a projected mid single-digit CAGR from 2021 to 2028 due to an increase in incidence and prevalence of cardiovascular, cancer, neurology, nephrology related conditions which require Iodine, Gadolinium, microbubble contrast agent and nuclear imaging agents to be administered intravascular.
The medical imaging agents market based on imaging is segmented into diagnostic and interventional imaging. Diagnostic imaging commanded the largest revenue in 2021 and is expected grow mid single-digit CAGR from 2021 to 2028. The interventional imaging segment is estimated to grow at early teens CAGR from 2021 to 2028 due to an increase in image guide procedures and an increase in the aging population who usually opt for minimally invasive procedures.
Medical imaging based on the end-user market is segmented into hospitals, diagnostic & ambulatory surgical centers and others which include academic and research institutes. The hospitals market accounted for the largest share in 2021, and the market is expected to grow at mid single-digit CAGR from 2021 to 2028, the rising demand for the diagnosis using CT or X-Ray, MRI, ultrasound, SPECT and PET imaging procedures due to increase in incidence and prevalence of diseases, the ready availability of cyclotrons for the generation of isotopes and presence of trained technicians who can handle radioisotopes. The diagnostic & Ambulatory surgical centers segment is the fastest-growing market and is estimated to grow at high single-digit CAGR from 2021 to 2028 due to an increase in the number of diagnostic procedures related to musculoskeletal (arthroscopy, imaging of spine), gastrointestinal (imaging of the abdomen, GI tract) and obstetrics & gynecology (hysterosalpingography).
Geographically, the market is segmented into North America, Europe, Asia-Pacific and RoW regions where the North America region commanded the largest revenue in 2021 and is expected to grow at mid single-digit CAGR from 2021 to 2028. Technological advancement in equipment increased utilization of fusion imaging and increase in incidence and prevalence of disease conditions requiring the use of diagnostic imaging have led the market growth in this region. However, the Asia-Pacific region is the fastest-growing market and is expected to grow at high single-digit CAGR from 2021 to 2028, due to increased healthcare awareness, improved economic growth, a large patient pool, and a rising aged population.
The Medical imaging agents global market is a competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares and also acquiring companies for product expansion. Some of the key players in the Medical imaging agents global market are GE Company (GE Healthcare) (U.S.), Bayer Group (Germany), Guerbet (France), Bracco Group (Italy), Curium Pharma (France), Cardinal Health (U.S), Lantheus Medical Imaging (U.S.), Sumitomo Chemicals (Japan), Novartis International AG (Advanced accelerator) (Switzerland), Fujifilm Holding Corporation (Japan), Fujipharma Co. Ltd (Japan), Jubilant Life science (India) and Beijing Beilu (China).
Medical imaging agents global market is segmented based on molecule/isotope, modality, application, route of administration, imaging and end-users. The market based on molecule/isotope segmented into contrast agents and nuclear imaging agents, where the contrast agents segment commanded the largest revenue in 2021 and the segment is expected to grow at mid single-digit CAGR from 2021 to 2028. The contrast agents global market is further segmented based on molecule into Iodine based [Ionic (Monomeric and Dimeric), Non-Ionic (Monomeric and Dimeric)], Gadolinium-based contrast agents [Macrocyclic (Ionic and Non-Ionic), Linear (Ionic and Non-Ionic)], microbubble based contrast agent and others which include Barium and iron-based contrast agents. Iodine-based contrast agents market contributed the largest revenue in 2021 and is expected grow at low single-digit CAGR of 4.7% from 2021 to 2028 and the microbubble segment is growing rapidly at late teen double-digit CAGR from 2021 to 2028 due to expansion in disease indications. Based on ionicity, the Iodine-based contrast agent is segmented into ionic and non-ionic. The non-Ionic Iodine-based contrast agents market accounted for the largest share in 2021 and the market is projected to grow at a mid single-digit CAGR from 2021 to 2028. Because of lower osmolality, better tolerance and another advantage, non-ionic iodine contrast agents are preferred and they are less toxic. Ionic Iodine based contrasts are further segmented based on chemical structure into monomers and dimers. Monomers accounted for the largest share in 2021 and is estimated to grow at a mid single-digit CAGR from 2021 to 2028. Non-Ionic as they are safer and tolerable when compared to ionic contrast agents and low osmolar agents do not dissociate into a particle in solution and help in reducing the neurotoxicity. The gadolinium contrast agents are further segmented based on chemical structures into macrocyclic and linear agents, among which the macrocyclic commanded the largest share in 2021 and is expected to grow at high single-digit CAGR from 2021 to 2028. Macrocyclic agents are further segmented into ionic and non-ionic agents, among which, non-ionic commanded the largest revenue in 2021 and is estimated to grow at a mid single-digit CAGR from 2021 to 2028. The Ionic segment is expected to grow at a high single-digit CAGR from 2021 to 2028.
As estimated by IQ4I Research, the nuclear imaging agents global market is poised to grow at mid single-digit CAGR from 2021 to 2028. Increased radioisotopes applications, rise in public awareness, use of SPECT/CT and PET/CT imaging scans, the abundance of radiopharmaceuticals, advancement in imaging technology (hybrid imaging) is boosting nuclear imaging agent's market growth. In addition, increasing need in emerging markets, production of radiopharmaceuticals from cyclotrons, efficient diagnosis and treatments, emerging radio isotopes and replacement of old/traditional equipment are the opportunities likely to propel the growth of the nuclear imaging agents market.
The nuclear imaging agents global market based on isotopes are segmented into Technetium (Tc-99m), Thallium (Tl-201), Gallium (Ga-67), Iodine (I-123), Xe-133, Rhenium (Re-186), Fluorodeoxyglucose (18F-FDG), Gallium (Ga-68), Rubidium (Rb-82) and others. Technetium (Tc-99m) isotope commanded the largest revenue in 2021 and is expected to grow at mid single-digit CAGR from 2021 to 2028 and Gallium (Ga-68) is projected to grow at high double-digit CAGR from 2021 to 2028 due to its increasing use in the diagnosis of neuroendocrine tumors and emerging use in prostate cancer.
The Medical imaging agents market based on modality is segmented into X-ray/CT, MRI, Ultrasound, SPECT and PET. X-Ray/CT market held the largest market revenue in 2021 and is expected to grow at low single-digit CAGR from 2021 to 2028 and the ultrasound segment is growing rapidly at late teen double digit CAGR from 2021 to 2028 due to increased use in diagnostic procedures especially echocardiography, focal liver lesions and ultrasonography of urinary tract.
The Medical imaging agents market based on applications is segmented into cardiovascular, cancer, gastrointestinal, musculoskeletal, neurology, nephrology, obstetrics & gynecology, pulmonary, hepatology and others which include neck, bone and salivary gland imaging. The cardiovascular market accounted for the largest share in 2021 and is expected grow at mid single-digit CAGR from 2021 to 2028 and cancer is the fastest-growing segment with a high single-digit CAGR from 2021 to 2028 due to an increase in cancer imaging such as lung, thyroid and breast cancer imaging procedures using Iodine, Gadolinium and microbubble contrast agents and radiopharmaceuticals.
Medical imaging agents market by route of administration is segmented into intravascular, oral, rectal and others, which include intraosseous, intrathecal and intravesical. Intravascular accounted for the largest share in 2021 and is the fastest-growing market with a projected mid single-digit CAGR from 2021 to 2028 due to an increase in incidence and prevalence of cardiovascular, cancer, neurology, nephrology related conditions which require Iodine, Gadolinium, microbubble contrast agent and nuclear imaging agents to be administered intravascular.
The medical imaging agents market based on imaging is segmented into diagnostic and interventional imaging. Diagnostic imaging commanded the largest revenue in 2021 and is expected grow mid single-digit CAGR from 2021 to 2028. The interventional imaging segment is estimated to grow at early teens CAGR from 2021 to 2028 due to an increase in image guide procedures and an increase in the aging population who usually opt for minimally invasive procedures.
Medical imaging based on the end-user market is segmented into hospitals, diagnostic & ambulatory surgical centers and others which include academic and research institutes. The hospitals market accounted for the largest share in 2021, and the market is expected to grow at mid single-digit CAGR from 2021 to 2028, the rising demand for the diagnosis using CT or X-Ray, MRI, ultrasound, SPECT and PET imaging procedures due to increase in incidence and prevalence of diseases, the ready availability of cyclotrons for the generation of isotopes and presence of trained technicians who can handle radioisotopes. The diagnostic & Ambulatory surgical centers segment is the fastest-growing market and is estimated to grow at high single-digit CAGR from 2021 to 2028 due to an increase in the number of diagnostic procedures related to musculoskeletal (arthroscopy, imaging of spine), gastrointestinal (imaging of the abdomen, GI tract) and obstetrics & gynecology (hysterosalpingography).
Geographically, the market is segmented into North America, Europe, Asia-Pacific and RoW regions where the North America region commanded the largest revenue in 2021 and is expected to grow at mid single-digit CAGR from 2021 to 2028. Technological advancement in equipment increased utilization of fusion imaging and increase in incidence and prevalence of disease conditions requiring the use of diagnostic imaging have led the market growth in this region. However, the Asia-Pacific region is the fastest-growing market and is expected to grow at high single-digit CAGR from 2021 to 2028, due to increased healthcare awareness, improved economic growth, a large patient pool, and a rising aged population.
The Medical imaging agents global market is a competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares and also acquiring companies for product expansion. Some of the key players in the Medical imaging agents global market are GE Company (GE Healthcare) (U.S.), Bayer Group (Germany), Guerbet (France), Bracco Group (Italy), Curium Pharma (France), Cardinal Health (U.S), Lantheus Medical Imaging (U.S.), Sumitomo Chemicals (Japan), Novartis International AG (Advanced accelerator) (Switzerland), Fujifilm Holding Corporation (Japan), Fujipharma Co. Ltd (Japan), Jubilant Life science (India) and Beijing Beilu (China).
1 EXECUTIVE SUMMARY
2 INTRODUCTION
2.1 KEY TAKEAWAYS
2.2 REPORT SCOPE
2.3 REPORT DESCRIPTION
2.4 MARKETS COVERED
2.5 STAKEHOLDERS
2.6 RESEARCH METHODOLOGY
2.6.1 MARKET SIZE ESTIMATION
2.6.2 MARKET CRACKDOWN AND DATA TRIANGULATION
2.6.3 SECONDARY SOURCES
2.6.4 PRIMARY SOURCES
2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES
2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES
2.6.7 ASSUMPTIONS
2.6.7.1 Procedural volume assumptions
3 MARKET ANALYSIS
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 FACTORS INFLUENCING MARKET
3.3.1 DRIVERS AND OPPORTUNITIES
3.3.1.1 Increasing demand for imaging agent-assisted diagnostic procedures
3.3.1.2 Production of radiopharmaceuticals from cyclotrons
3.3.1.3 The growth of medical imaging technologies in emerging markets
3.3.1.4 Usage of hybrid imaging
3.3.1.5 Increasing geriatric population suffering from chronic disease
3.3.2 RESTRAINTS AND THREATS
3.3.2.1 Side effects associated with medical imaging agents
3.3.2.2 The shorter half-life of radiopharmaceuticals
3.3.2.3 Shortage of radiologist and qualified technicians
3.3.2.4 High cost and supply shortage of isotopes
3.3.2.5 Uncertainty due to fall out of genus case which could lead to the reclassification of imaging agents as medical devices resulting in additional expenses for the companies.
3.4 REGULATORY GUIDELINES
3.4.1 UNITED STATES
3.4.2 EUROPE
3.4.3 CHINA
3.4.4 JAPAN
3.4.5 INDIA
3.4.6 SOUTH KOREA
3.5 REIMBURSEMENT TABLE
3.6 CLINICAL TRIALS
3.7 SUPPLY CHAIN ANALYSIS OF NUCLEAR MEDICINE
3.7.1 REACTORS/IRRADIATORS
3.7.2 PROCESSING FACILITY
3.7.3 GENERATORS
3.7.4 HOSPITALS AND CENTRAL RADIO PHARMACIES
3.7.5 CYCLOTRON
3.7.6 LINAC BASED TC-99M PRODUCTION METHOD
3.8 SUPPLY CHAIN ANALYSIS OF CONTRAST AGENTS
3.9 LIST OF FDA APPROVED RADIOPHARMACEUTICALS
3.10 PORTER’S FIVE FORCE ANALYSIS
3.10.1 THREAT OF NEW ENTRANTS
3.10.2 THREAT OF SUBSTITUTES
3.10.3 RIVALRY AMONG EXISTING COMPETITORS
3.10.4 BARGAINING POWER OF SUPPLIERS
3.10.5 BARGAINING POWER OF BUYERS
3.11 TECHNOLOGICAL ADVANCEMENTS
3.11.1 ADVANCEMENTS IN COMPUTED TOMOGRAPHY TECHNOLOGY
3.11.2 ADVANCEMENTS IN MRI CONTRAST AGENTS
3.11.3 APPLICATION OF AI IN CONTRAST IMAGING
3.11.4 XENON MAGNETIC RESONANCE IMAGING
3.11.5 LINAC BASED TC-99M PRODUCTION
3.12 MARKET SHARE ANALYSIS
3.12.1 MARKET SHARE ANALYSIS BY MAJOR PLAYERS
3.12.2 MARKET SHARE ANALYSIS OF MRI
3.12.3 MARKET SHARE ANALYSIS OF X-RAY/CT
3.12.4 MARKET SHARE ANALYSIS OF ULTRASOUND AGENTS
3.12.5 MARKET SHARE ANALYSIS OF SPECT AGENTS
3.12.6 MARKET SHARE ANALYSIS OF PET AGENTS
3.13 MEDICAL IMAGING AGENTS MARKET – NUMBER OF SCANS, VOLUME OF IMAGING AGENTS CONSUMED, AND MARKET SIZE
3.13.1 GLOBAL X-RAY/COMPUTED TOMOGRAPHY MARKET - NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE
3.13.2 NORTH AMERICA COMPUTED TOMOGRAPHY MARKET - NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE
3.13.3 EUROPE COMPUTED TOMOGRAPHY MARKET - NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE
3.13.4 APAC COMPUTED TOMOGRAPHY MARKET - NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE
3.13.5 ROW COMPUTED TOMOGRAPHY MARKET - NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE
3.14 MAGNETIC RESONANCE IMAGING MARKET - PROCEDURE VOLUME, VOLUME OF CONTRAST AGENT CONSUMED & MARKET SIZE
3.14.1 GLOBAL MAGNETIC RESONANCE IMAGING MARKET - NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE
3.14.2 NORTH AMERICA MAGNETIC RESONANCE IMAGING MARKET - NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE
3.14.3 EUROPE MAGNETIC RESONANCE IMAGING MARKET - NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE
3.14.4 APAC MAGNETIC RESONANCE IMAGING MARKET - NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE
3.14.5 ROW MAGNETIC RESONANCE IMAGING MARKET - NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE
3.15 MEDICAL IMAGING AGENTS-FUNDING SCENARIO
3.16 MEDICAL IMAGING AGENTS– DEALS AND APPROVALS
3.17 SPECT, PET, CT MRI AND CYCLOTRONS INSTALLED BASE
4 MEDICAL IMAGING AGENTS GLOBAL MARKET, BASED ON MOLECULE/ISOTOPE
4.1 INTRODUCTION
4.2 CONTRAST AGENTS
4.2.1 IODINATED CONTRAST AGENTS
4.2.1.1 Iodinated Ionic Contrast Agents
4.2.1.2 Iodinated Non-Ionic Contrast Agents
4.2.1.2.1 Monomer
4.2.1.2.2 Dimer
4.2.2 GADOLINIUM-BASED CONTRAST AGENTS
4.2.2.1 Macrocyclic Contrast Agents
4.2.2.1.1 Macrocyclic Ionic Contrast Agents
4.2.2.1.2 Macrocyclic Non-Ionic Contrast Agents
4.2.2.2 Linear Gadolinium-Based Contrast Agents
4.2.2.2.1 Linear Ionic Contrast Agents
4.2.2.2.2 Linear Non-Ionic Contrast Agents
4.2.3 MICROBUBBLE CONTRAST AGENTS
4.2.4 OTHERS CONTRAST AGENTS
4.3 NUCLEAR IMAGING AGENTS
4.3.1 TECHNETIUM (TC-99M)
4.3.2 THALLIUM (TL-201)
4.3.3 GALLIUM (GA-67)
4.3.4 IODINE (I-123)
4.3.4.1 Supply chain analysis of Iodine-123 (I-123)
4.3.5 XENON (XE-133)
4.3.6 RHENIUM (RE-186)
4.3.7 FLUORODEOXYGLUCOSE (18F-FDG)
4.3.7.1 Supply chain analysis of Fluorine-18 (F-18)
4.3.8 GALLIUM (GA-68)
4.3.8.1 Supply chain analysis of Gallium-68 (Ga-68)
4.3.8.2 Characteristics of current Ge-68/Ga-68 Generators
4.3.9 RUBIDIUM (RB-82)
4.3.9.1 Production analysis of Strontium (Sr-82)/ Rubidium (Rb-82)
4.3.10 OTHERS
5 MEDICAL IMAGING AGENTS GLOBAL MARKET, BASED ON MODALITY
5.1 INTRODUCTION
5.2 X-RAY/COMPUTED TOMOGRAPHY (CT)
5.3 MAGNETIC RESONANCE IMAGING (MRI)
5.4 ULTRASOUND
5.5 SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT)
5.6 POSITRON EMISSION TOMOGRAPHY (PET)
6 MEDICAL IMAGING AGENTS GLOBAL MARKET, BASED ON APPLICATION
6.1 INTRODUCTION
6.2 CARDIOVASCULAR
6.3 CANCER
6.4 GASTROINTESTINAL
6.5 MUSCULOSKELETAL
6.6 NEUROLOGY
6.7 NEPHROLOGY
6.8 OBSTETRICS AND GYNECOLOGY
6.9 PULMONARY
6.10 HEPATOLOGY
6.11 OTHERS
7 MEDICAL IMAGING AGENTS GLOBAL MARKET, BASED ON ROUTE OF ADMINISTRATION
7.1 INTRODUCTION
7.2 INTRAVASCULAR
7.3 ORAL
7.4 RECTAL
7.5 OTHERS
8 MEDICAL IMAGING AGENTS GLOBAL MARKET, BASED ON IMAGING
8.1 INTRODUCTION
8.2 DIAGNOSTIC IMAGING
8.3 INTERVENTIONAL IMAGING
9 MEDICAL IMAGING AGENTS GLOBAL MARKET, BASED ON END-USERS
9.1 INTRODUCTION
9.2 HOSPITAL
9.3 DIAGNOSTIC & AMBULATORY SURGICAL CENTERS
9.4 OTHER END-USER
10 REGIONAL ANALYSIS
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 THE U.S.
10.2.2 REST OF N.A.
10.3 EUROPE
10.3.1 GERMANY
10.3.2 FRANCE
10.3.3 ITALY
10.3.4 REST OF EUROPE
10.4 ASIA-PACIFIC
10.4.1 CHINA
10.4.2 JAPAN
10.4.3 SOUTH KOREA
10.4.4 REST OF APAC
10.5 REST OF THE WORLD
10.5.1 TURKEY
10.5.2 BRAZIL
10.5.3 OTHERS
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 APPROVALS
11.3 ACQUISITIONS
11.4 AGREEMENTS
11.5 PARTNERSHIPS
11.6 EXPANSION
11.7 OTHERS
12 MAJOR PLAYERS PROFILE
12.1 BAYER GROUP
12.1.1 OVERVIEW
12.1.2 FINANCIALS
12.1.3 PRODUCT PORTFOLIO
12.1.4 KEY DEVELOPMENTS
12.1.5 BUSINESS STRATEGY
12.1.6 SWOT ANALYSIS
12.2 BRACCO GROUP
12.2.1 OVERVIEW
12.2.2 FINANCIALS
12.2.3 PRODUCT PORTFOLIO
12.2.4 KEY DEVELOPMENTS
12.2.5 BUSINESS STRATEGY
12.2.6 SWOT ANALYSIS
12.3 CARDINAL HEALTH INC.
12.3.1 OVERVIEW
12.3.2 FINANCIALS
12.3.3 PRODUCT PORTFOLIO
12.3.4 KEY DEVELOPMENTS
12.3.5 BUSINESS STRATEGY
12.3.6 SWOT ANALYSIS
12.4 CURIUM PHARMA
12.4.1 OVERVIEW
12.4.2 FINANCIALS
12.4.3 PRODUCT PORTFOLIO
12.4.4 KEY DEVELOPMENTS
12.4.5 BUSINESS STRATEGY
12.4.6 SWOT ANALYSIS
12.5 FUJIFILM HOLDINGS CORPORATION
12.5.1 OVERVIEW
12.5.2 FINANCIALS
12.5.3 PRODUCT PORTFOLIO
12.5.4 KEY DEVELOPMENTS
12.5.5 BUSINESS STRATEGY
12.5.6 SWOT ANALYSIS
12.6 GE COMPANY (GE HEALTHCARE)
12.6.1 OVERVIEW
12.6.2 FINANCIALS
12.6.3 PRODUCT PORTFOLIO
12.6.4 KEY DEVELOPMENTS
12.6.5 BUSINESS STRATEGY
12.6.6 SWOT ANALYSIS
12.7 GUERBET
12.7.1 OVERVIEW
12.7.2 FINANCIALS
12.7.3 PRODUCT PORTFOLIO
12.7.4 KEY DEVELOPMENTS
12.7.5 BUSINESS STRATEGY
12.7.6 SWOT ANALYSIS
12.8 LANTHEUS MEDICAL IMAGING INC.
12.8.1 OVERVIEW
12.8.2 FINANCIALS
12.8.3 PRODUCT PORTFOLIO
12.8.4 KEY DEVELOPMENTS
12.8.5 BUSINESS STRATEGY
12.8.6 SWOT ANALYSIS
12.9 NOVARTIS INTERNATIONAL AG
12.9.1 OVERVIEW
12.9.2 FINANCIALS
12.9.3 PRODUCT PORTFOLIO
12.9.4 KEY DEVELOPMENTS
12.9.5 BUSINESS STRATEGY
12.9.6 SWOT ANALYSIS
12.10 SUMITOMO CHEMICALS
12.10.1 OVERVIEW
12.10.2 FINANCIALS
12.10.3 PRODUCT PORTFOLIO
12.10.4 KEY DEVELOPMENTS
12.10.5 BUSINESS STRATEGY
12.10.6 SWOT ANALYSIS
2 INTRODUCTION
2.1 KEY TAKEAWAYS
2.2 REPORT SCOPE
2.3 REPORT DESCRIPTION
2.4 MARKETS COVERED
2.5 STAKEHOLDERS
2.6 RESEARCH METHODOLOGY
2.6.1 MARKET SIZE ESTIMATION
2.6.2 MARKET CRACKDOWN AND DATA TRIANGULATION
2.6.3 SECONDARY SOURCES
2.6.4 PRIMARY SOURCES
2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES
2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES
2.6.7 ASSUMPTIONS
2.6.7.1 Procedural volume assumptions
3 MARKET ANALYSIS
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 FACTORS INFLUENCING MARKET
3.3.1 DRIVERS AND OPPORTUNITIES
3.3.1.1 Increasing demand for imaging agent-assisted diagnostic procedures
3.3.1.2 Production of radiopharmaceuticals from cyclotrons
3.3.1.3 The growth of medical imaging technologies in emerging markets
3.3.1.4 Usage of hybrid imaging
3.3.1.5 Increasing geriatric population suffering from chronic disease
3.3.2 RESTRAINTS AND THREATS
3.3.2.1 Side effects associated with medical imaging agents
3.3.2.2 The shorter half-life of radiopharmaceuticals
3.3.2.3 Shortage of radiologist and qualified technicians
3.3.2.4 High cost and supply shortage of isotopes
3.3.2.5 Uncertainty due to fall out of genus case which could lead to the reclassification of imaging agents as medical devices resulting in additional expenses for the companies.
3.4 REGULATORY GUIDELINES
3.4.1 UNITED STATES
3.4.2 EUROPE
3.4.3 CHINA
3.4.4 JAPAN
3.4.5 INDIA
3.4.6 SOUTH KOREA
3.5 REIMBURSEMENT TABLE
3.6 CLINICAL TRIALS
3.7 SUPPLY CHAIN ANALYSIS OF NUCLEAR MEDICINE
3.7.1 REACTORS/IRRADIATORS
3.7.2 PROCESSING FACILITY
3.7.3 GENERATORS
3.7.4 HOSPITALS AND CENTRAL RADIO PHARMACIES
3.7.5 CYCLOTRON
3.7.6 LINAC BASED TC-99M PRODUCTION METHOD
3.8 SUPPLY CHAIN ANALYSIS OF CONTRAST AGENTS
3.9 LIST OF FDA APPROVED RADIOPHARMACEUTICALS
3.10 PORTER’S FIVE FORCE ANALYSIS
3.10.1 THREAT OF NEW ENTRANTS
3.10.2 THREAT OF SUBSTITUTES
3.10.3 RIVALRY AMONG EXISTING COMPETITORS
3.10.4 BARGAINING POWER OF SUPPLIERS
3.10.5 BARGAINING POWER OF BUYERS
3.11 TECHNOLOGICAL ADVANCEMENTS
3.11.1 ADVANCEMENTS IN COMPUTED TOMOGRAPHY TECHNOLOGY
3.11.2 ADVANCEMENTS IN MRI CONTRAST AGENTS
3.11.3 APPLICATION OF AI IN CONTRAST IMAGING
3.11.4 XENON MAGNETIC RESONANCE IMAGING
3.11.5 LINAC BASED TC-99M PRODUCTION
3.12 MARKET SHARE ANALYSIS
3.12.1 MARKET SHARE ANALYSIS BY MAJOR PLAYERS
3.12.2 MARKET SHARE ANALYSIS OF MRI
3.12.3 MARKET SHARE ANALYSIS OF X-RAY/CT
3.12.4 MARKET SHARE ANALYSIS OF ULTRASOUND AGENTS
3.12.5 MARKET SHARE ANALYSIS OF SPECT AGENTS
3.12.6 MARKET SHARE ANALYSIS OF PET AGENTS
3.13 MEDICAL IMAGING AGENTS MARKET – NUMBER OF SCANS, VOLUME OF IMAGING AGENTS CONSUMED, AND MARKET SIZE
3.13.1 GLOBAL X-RAY/COMPUTED TOMOGRAPHY MARKET - NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE
3.13.2 NORTH AMERICA COMPUTED TOMOGRAPHY MARKET - NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE
3.13.3 EUROPE COMPUTED TOMOGRAPHY MARKET - NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE
3.13.4 APAC COMPUTED TOMOGRAPHY MARKET - NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE
3.13.5 ROW COMPUTED TOMOGRAPHY MARKET - NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE
3.14 MAGNETIC RESONANCE IMAGING MARKET - PROCEDURE VOLUME, VOLUME OF CONTRAST AGENT CONSUMED & MARKET SIZE
3.14.1 GLOBAL MAGNETIC RESONANCE IMAGING MARKET - NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE
3.14.2 NORTH AMERICA MAGNETIC RESONANCE IMAGING MARKET - NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE
3.14.3 EUROPE MAGNETIC RESONANCE IMAGING MARKET - NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE
3.14.4 APAC MAGNETIC RESONANCE IMAGING MARKET - NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE
3.14.5 ROW MAGNETIC RESONANCE IMAGING MARKET - NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE
3.15 MEDICAL IMAGING AGENTS-FUNDING SCENARIO
3.16 MEDICAL IMAGING AGENTS– DEALS AND APPROVALS
3.17 SPECT, PET, CT MRI AND CYCLOTRONS INSTALLED BASE
4 MEDICAL IMAGING AGENTS GLOBAL MARKET, BASED ON MOLECULE/ISOTOPE
4.1 INTRODUCTION
4.2 CONTRAST AGENTS
4.2.1 IODINATED CONTRAST AGENTS
4.2.1.1 Iodinated Ionic Contrast Agents
4.2.1.2 Iodinated Non-Ionic Contrast Agents
4.2.1.2.1 Monomer
4.2.1.2.2 Dimer
4.2.2 GADOLINIUM-BASED CONTRAST AGENTS
4.2.2.1 Macrocyclic Contrast Agents
4.2.2.1.1 Macrocyclic Ionic Contrast Agents
4.2.2.1.2 Macrocyclic Non-Ionic Contrast Agents
4.2.2.2 Linear Gadolinium-Based Contrast Agents
4.2.2.2.1 Linear Ionic Contrast Agents
4.2.2.2.2 Linear Non-Ionic Contrast Agents
4.2.3 MICROBUBBLE CONTRAST AGENTS
4.2.4 OTHERS CONTRAST AGENTS
4.3 NUCLEAR IMAGING AGENTS
4.3.1 TECHNETIUM (TC-99M)
4.3.2 THALLIUM (TL-201)
4.3.3 GALLIUM (GA-67)
4.3.4 IODINE (I-123)
4.3.4.1 Supply chain analysis of Iodine-123 (I-123)
4.3.5 XENON (XE-133)
4.3.6 RHENIUM (RE-186)
4.3.7 FLUORODEOXYGLUCOSE (18F-FDG)
4.3.7.1 Supply chain analysis of Fluorine-18 (F-18)
4.3.8 GALLIUM (GA-68)
4.3.8.1 Supply chain analysis of Gallium-68 (Ga-68)
4.3.8.2 Characteristics of current Ge-68/Ga-68 Generators
4.3.9 RUBIDIUM (RB-82)
4.3.9.1 Production analysis of Strontium (Sr-82)/ Rubidium (Rb-82)
4.3.10 OTHERS
5 MEDICAL IMAGING AGENTS GLOBAL MARKET, BASED ON MODALITY
5.1 INTRODUCTION
5.2 X-RAY/COMPUTED TOMOGRAPHY (CT)
5.3 MAGNETIC RESONANCE IMAGING (MRI)
5.4 ULTRASOUND
5.5 SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT)
5.6 POSITRON EMISSION TOMOGRAPHY (PET)
6 MEDICAL IMAGING AGENTS GLOBAL MARKET, BASED ON APPLICATION
6.1 INTRODUCTION
6.2 CARDIOVASCULAR
6.3 CANCER
6.4 GASTROINTESTINAL
6.5 MUSCULOSKELETAL
6.6 NEUROLOGY
6.7 NEPHROLOGY
6.8 OBSTETRICS AND GYNECOLOGY
6.9 PULMONARY
6.10 HEPATOLOGY
6.11 OTHERS
7 MEDICAL IMAGING AGENTS GLOBAL MARKET, BASED ON ROUTE OF ADMINISTRATION
7.1 INTRODUCTION
7.2 INTRAVASCULAR
7.3 ORAL
7.4 RECTAL
7.5 OTHERS
8 MEDICAL IMAGING AGENTS GLOBAL MARKET, BASED ON IMAGING
8.1 INTRODUCTION
8.2 DIAGNOSTIC IMAGING
8.3 INTERVENTIONAL IMAGING
9 MEDICAL IMAGING AGENTS GLOBAL MARKET, BASED ON END-USERS
9.1 INTRODUCTION
9.2 HOSPITAL
9.3 DIAGNOSTIC & AMBULATORY SURGICAL CENTERS
9.4 OTHER END-USER
10 REGIONAL ANALYSIS
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 THE U.S.
10.2.2 REST OF N.A.
10.3 EUROPE
10.3.1 GERMANY
10.3.2 FRANCE
10.3.3 ITALY
10.3.4 REST OF EUROPE
10.4 ASIA-PACIFIC
10.4.1 CHINA
10.4.2 JAPAN
10.4.3 SOUTH KOREA
10.4.4 REST OF APAC
10.5 REST OF THE WORLD
10.5.1 TURKEY
10.5.2 BRAZIL
10.5.3 OTHERS
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 APPROVALS
11.3 ACQUISITIONS
11.4 AGREEMENTS
11.5 PARTNERSHIPS
11.6 EXPANSION
11.7 OTHERS
12 MAJOR PLAYERS PROFILE
12.1 BAYER GROUP
12.1.1 OVERVIEW
12.1.2 FINANCIALS
12.1.3 PRODUCT PORTFOLIO
12.1.4 KEY DEVELOPMENTS
12.1.5 BUSINESS STRATEGY
12.1.6 SWOT ANALYSIS
12.2 BRACCO GROUP
12.2.1 OVERVIEW
12.2.2 FINANCIALS
12.2.3 PRODUCT PORTFOLIO
12.2.4 KEY DEVELOPMENTS
12.2.5 BUSINESS STRATEGY
12.2.6 SWOT ANALYSIS
12.3 CARDINAL HEALTH INC.
12.3.1 OVERVIEW
12.3.2 FINANCIALS
12.3.3 PRODUCT PORTFOLIO
12.3.4 KEY DEVELOPMENTS
12.3.5 BUSINESS STRATEGY
12.3.6 SWOT ANALYSIS
12.4 CURIUM PHARMA
12.4.1 OVERVIEW
12.4.2 FINANCIALS
12.4.3 PRODUCT PORTFOLIO
12.4.4 KEY DEVELOPMENTS
12.4.5 BUSINESS STRATEGY
12.4.6 SWOT ANALYSIS
12.5 FUJIFILM HOLDINGS CORPORATION
12.5.1 OVERVIEW
12.5.2 FINANCIALS
12.5.3 PRODUCT PORTFOLIO
12.5.4 KEY DEVELOPMENTS
12.5.5 BUSINESS STRATEGY
12.5.6 SWOT ANALYSIS
12.6 GE COMPANY (GE HEALTHCARE)
12.6.1 OVERVIEW
12.6.2 FINANCIALS
12.6.3 PRODUCT PORTFOLIO
12.6.4 KEY DEVELOPMENTS
12.6.5 BUSINESS STRATEGY
12.6.6 SWOT ANALYSIS
12.7 GUERBET
12.7.1 OVERVIEW
12.7.2 FINANCIALS
12.7.3 PRODUCT PORTFOLIO
12.7.4 KEY DEVELOPMENTS
12.7.5 BUSINESS STRATEGY
12.7.6 SWOT ANALYSIS
12.8 LANTHEUS MEDICAL IMAGING INC.
12.8.1 OVERVIEW
12.8.2 FINANCIALS
12.8.3 PRODUCT PORTFOLIO
12.8.4 KEY DEVELOPMENTS
12.8.5 BUSINESS STRATEGY
12.8.6 SWOT ANALYSIS
12.9 NOVARTIS INTERNATIONAL AG
12.9.1 OVERVIEW
12.9.2 FINANCIALS
12.9.3 PRODUCT PORTFOLIO
12.9.4 KEY DEVELOPMENTS
12.9.5 BUSINESS STRATEGY
12.9.6 SWOT ANALYSIS
12.10 SUMITOMO CHEMICALS
12.10.1 OVERVIEW
12.10.2 FINANCIALS
12.10.3 PRODUCT PORTFOLIO
12.10.4 KEY DEVELOPMENTS
12.10.5 BUSINESS STRATEGY
12.10.6 SWOT ANALYSIS
LIST OF TABLES
TABLE 1 MEDICAL IMAGING AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 2 MEDICAL IMAGING AGENTS CLINICAL TRIALS
TABLE 3 TECHNETIUM (TC-99M) CURRENT IRRADIATORS
TABLE 4 TECHNETIUM (TC-99M) POTENTIAL IRRADIATORS
TABLE 5 TECHNETIUM (TC-99M) POTENTIAL IRRADIATORS
TABLE 6 TECHNETIUM (TC-99M) CURRENT PROCESSORS
TABLE 7 POTENTIAL PROCESSORS ENTERING THE GLOBAL SUPPLY CHAIN
TABLE 8 FDA APPROVED DIAGNOSTIC RADIOPHARMACEUTICALS
TABLE 9 X-RAY/ CT CONTRAST AGENT MEDIATED GLOBAL PROCEDURE VOLUME, (2020-2028) (MN)
TABLE 10 X-RAY/ CT CONTRAST AGENT GLOBAL CONSUMPTION, (2020-2028) (MN L)
TABLE 11 MRI CONTRAST AGENT CONTRAST MEDIATED GLOBAL PROCEDURE VOLUME, (2020-2028) (MN)
TABLE 12 MRI CONTRAST AGENTS GLOBAL CONSUMPTION, (2020-2028) (MN L)
TABLE 13 ULTRASOUND CONTRAST AGENTS MEDIATED PROCEDURE VOLUME, (2020-2028) (MN)
TABLE 14 ULTRASOUND CONTRAST AGENTS GLOBAL CONSUMPTION, (2020-2028) (L)
TABLE 15 MEDICAL IMAGING AGENTS GLOBAL MARKET REVENUE, BASED ON MOLECULE/ISOTOPE, (2020-2028) ($MN)
TABLE 16 CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 17 CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON MOLECULE, (2020-2028) ($MN)
TABLE 18 IODINATED CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 19 IODINATED CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON IONICITY, (2020-2028) ($MN)
TABLE 20 IODINATED IONIC CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 21 IODINATED NON-IONIC CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 22 NON-IONIC CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON CHEMICAL STRUCTURE, (2020-2028) ($MN)
TABLE 23 NON-IONIC MONOMER CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 24 NON-IONIC DIMER CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 25 GADOLINIUM BASED CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON CHEMICAL STRUCTURE, (2020-2028) ($MN)
TABLE 26 GADOLINIUM BASED CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 27 MACROCYCLIC CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 28 MACROCYCLIC CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON IONICITY, (2020-2028) ($MN)
TABLE 29 MACROCYCLIC IONIC CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 30 MACROCYCLIC NON-IONIC CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 31 LINEAR GADOLINIUM BASED CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 32 LINEAR GADOLINIUM BASED CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON IONICITY, (2020-2028) ($MN)
TABLE 33 LINEAR IONIC CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 34 LINEAR NON-IONIC CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 35 MICROBUBBLE CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 36 OTHER CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 37 NUCLEAR IMAGING AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 38 NUCLEAR IMAGING AGENTS GLOBAL MARKET REVENUE, BASED ON ISOTOPE, (2020-2028) ($MN)
TABLE 39 TECHNETIUM (TC-99M) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 40 THALLIUM (TL-201) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 41 GALLIUM (GA-67) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 42 IODINE (I-123) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 43 XENON (XE-133) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 44 RHENIUM (RE-186) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 45 FLUORODEOXYGLUCOSE(18F-FDG) GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 46 GALLIUM (GA-68) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 47 GALLIUM (GA-68) GENERATOR SUPPLIERS AND ITS CHARACTERISTICS
TABLE 48 RUBIDIUM (RB-82) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 49 STRONTIUM (SR-82)/RUBIDIUM (RB-82) GENERATOR SUPPLIERS
TABLE 50 OTHER ISOTOPES GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 51 MEDICAL IMAGING AGENTS GLOBAL MARKET REVENUE, BASED ON MODALITY, (2020-2028) ($MN)
TABLE 52 X-RAY/CT MODALITY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 53 MRI MODALITY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 54 ULTRASOUND MODALITY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 55 SPECT MODALITY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 56 PET MODALITY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 57 MEDICAL IMAGING AGENTS GLOBAL MARKET REVENUE, BASED ON APPLICATION, (2020-2028) ($MN)
TABLE 58 CARDIOVASCULAR APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 59 CANCER APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 60 GASTROINTESTINAL APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 61 MUSCULOSKELETAL APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 62 NEUROLOGY APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 63 NEPHROLOGY APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 64 OBSTETRICS AND GYNECOLOGY APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 65 PULMONARY APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 66 HEPATOLOGY APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 67 OTHER APPLICATIONS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 68 MEDICAL IMAGING AGENTS GLOBAL MARKET REVENUE, BASED ON ROUTE OF ADMINISTRATION, (2020-2028) ($MN)
TABLE 69 INTRAVASCULAR ROUTE OF ADMINISTRATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 70 ORAL ROUTE OF ADMINISTRATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 71 RECTAL ROUTE OF ADMINISTRATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 72 OTHER ROUTE OF ADMINISTRATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 73 MEDICAL IMAGING AGENTS GLOBAL MARKET REVENUE, BASED ON IMAGING, (2020-2028) ($MN)
TABLE 74 DIAGNOSTIC IMAGING GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 75 INTERVENTIONAL IMAGING GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 76 MEDICAL IMAGING AGENTS GLOBAL MARKET REVENUE, BASED ON END-USER, (2020-2028) ($MN)
TABLE 77 HOSPITAL GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 78 DIAGNOSTIC & AMBULATORY SURGICAL CENTERS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 79 OTHER END-USER GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 80 MEDICAL IMAGING AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 81 NORTH AMERICA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPE, (2020-2028) ($MN)
TABLE 82 NORTH-AMERICA CONTRAST AGENTS MARKET REVENUE, BASED ON MOLECULE, (2020-2028) ($MN)
TABLE 83 NORTH-AMERICA IODINATED CONTRAST AGENTS MARKET REVENUE, BASED ON IONICITY, (2020-2028) ($MN)
TABLE 84 NORTH-AMERICA NON-IONIC CONTRAST AGENTS MARKET REVENUE, BASED ON CHEMICAL STRUCTURE,(2020-2028) ($MN)
TABLE 85 NORTH-AMERICA GADOLINIUM CONTRAST AGENTS MARKET REVENUE, BASED ON CHEMICAL STRUCTURE, (2020-2028) ($MN)
TABLE 86 NORTH-AMERICA MACROCYCLIC CONTRAST AGENTS MARKET REVENUE, BASED ON IONICITY, (2020-2028) ($MN)
TABLE 87 NORTH-AMERICA LINEAR CONTRAST AGENTS MARKET REVENUE, BASED ON IONICITY, (2020-2028) ($MN)
TABLE 88 NORTH-AMERICA NUCLEAR IMAGING AGENTS MARKET REVENUE, BASED ON ISOTOPE, (2020-2028) ($MN)
TABLE 89 NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY, (2020-2028) ($MN)
TABLE 90 NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION, (2020-2028) ($MN)
TABLE 91 NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON ROUTE OF ADMINISTRATION, (2020-2028) ($MN)
TABLE 92 NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING, (2020-2028) ($MN)
TABLE 93 NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON END-USER, (2020-2028) ($MN)
TABLE 94 NORTH AMERICA SPECT, PET, CT MRI AND CYCLOTRONS INSTALLED BASE
TABLE 95 NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON COUNTRY, (2020-2028) ($MN)
TABLE 96 EUROPE MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPE, (2020-2028) ($MN)
TABLE 97 EUROPE CONTRAST AGENTS MARKET REVENUE, BASED ON MOLECULE, (2020-2028) ($MN)
TABLE 98 EUROPE IODINATED CONTRAST AGENTS MARKET REVENUE, BASED ON IONICITY, (2020-2028) ($MN)
TABLE 99 EUROPE NON-IONIC CONTRAST AGENTS MARKET REVENUE, BASED ON CHEMICAL STRUCTURE, (2020-2028) ($MN)
TABLE 100 EUROPE GADOLINIUM BASED CONTRAST AGENTS MARKET REVENUE, BASED ON CHEMICAL STRUCTURE, (2020-2028) ($MN)
TABLE 101 EUROPE MACROCYCLIC CONTRAST AGENTS MARKET REVENUE, BASED ON IONICITY, (2020-2028) ($MN)
TABLE 102 EUROPE LINEAR CONTRAST AGENTS MARKET REVENUE, BASED ON IONICITY, (2020-2028) ($MN)
TABLE 103 EUROPE NUCLEAR IMAGING AGENTS MARKET REVENUE, BASED ON ISOTOPE, (2020-2028) ($MN)
TABLE 104 EUROPE MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY, (2020-2028) ($MN)
TABLE 105 EUROPE MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION, (2020-2028) ($MN)
TABLE 106 EUROPE MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON ROUTE OF ADMINISTRATION, (2020-2028) ($MN)
TABLE 107 EUROPE MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING (2020-2028) ($MN)
TABLE 108 EUROPE MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON END-USER,(2020-2028) ($MN)
TABLE 109 EUROPE SPECT, PET, CT MRI AND CYCLOTRONS INSTALLED BASE
TABLE 110 EUROPE MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON COUNTRY, (2020-2028) ($MN)
TABLE 111 APAC MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPE, (2020-2028) ($MN)
TABLE 112 APAC CONTRAST AGENTS MARKET REVENUE, BASED ON MOLECULE, (2020-2028) ($MN)
TABLE 113 APAC IODINATED CONTRAST AGENTS MARKET REVENUE, BASED ON IONICITY,(2020-2028) ($MN)
TABLE 114 APAC NON-IONIC CONTRAST AGENTS MARKET REVENUE, BASED ON CHEMICAL STRUCTURE, (2020-2028) ($MN)
TABLE 115 APAC GADOLINIUM BASED CONTRAST AGENTS MARKET REVENUE, BASED ON CHEMICAL STRUCTURE, (2020-2028) ($MN)
TABLE 116 APAC MACROCYCLIC CONTRAST AGENTS MARKET REVENUE, BASED ON IONICITY, (2020-2028) ($MN)
TABLE 117 APAC LINEAR CONTRAST AGENTS MARKET REVENUE, BASED ON IONICITY, (2020-2028) ($MN)
TABLE 118 APAC NUCLEAR IMAGING AGENTS MARKET REVENUE, BASED ON ISOTOPE, (2020-2028) ($MN)
TABLE 119 APAC MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY, (2020-2028) ($MN)
TABLE 120 APAC MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION, (2020-2028) ($MN)
TABLE 121 APAC MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON ROUTE OF ADMINISTRATION, (2020-2028) ($MN)
TABLE 122 APAC MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING (2020-2028) ($MN)
TABLE 123 APAC MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON END-USER, (2020-2028) ($MN)
TABLE 124 ASIA-PACIFIC SPECT, PET, CT MRI AND CYCLOTRONS INSTALLED BASE
TABLE 125 APAC MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON COUNTRY, (2020-2028) ($MN)
TABLE 126 ROW MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPE, (2020-2028) ($MN)
TABLE 127 ROW CONTRAST AGENTS MARKET REVENUE, BASED ON MOLECULE, (2020-2028) ($MN)
TABLE 128 ROW IODINATED CONTRAST AGENTS MARKET REVENUE, BASED ON IONICITY, (2020-2028) ($MN)
TABLE 129 ROW NON-IONIC CONTRAST AGENTS MARKET REVENUE, BASED ON CHEMICAL STRUCTURE, (2020-2028) ($MN)
TABLE 130 ROW GADOLINIUM BASED CONTRAST AGENTS MARKET REVENUE, BASED ON CHEMICAL STRUCTURE, (2020-2028) ($MN)
TABLE 131 ROW MACROCYCLIC CONTRAST AGENTS MARKET REVENUE, BASED ON IONICITY, (2020-2028) ($MN)
TABLE 132 ROW LINEAR CONTRAST AGENTS MARKET REVENUE, BASED ON IONICITY, (2020-2028) ($MN)
TABLE 133 ROW NUCLEAR IMAGING AGENTS MARKET REVENUE, BASED ON ISOTOPE, (2020-2028) ($MN)
TABLE 134 ROW MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY, (2020-2028) ($MN)
TABLE 135 ROW MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION, (2020-2028) ($MN)
TABLE 136 ROW MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON ROUTE OF ADMINISTRATION, (2020-2028) ($MN)
TABLE 137 ROW MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING (2020-2028) ($MN)
TABLE 138 ROW MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON END-USER, (2020-2028) ($MN)
TABLE 139 ROW SPECT, PET, CT MRI AND CYCLOTRONS INSTALLED BASE
TABLE 140 ROW MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON COUNTRY, (2020-2028) ($MN)
TABLE 141 APPROVALS (2020-2021)
TABLE 142 ACQUISITIONS, (2020-2021)
TABLE 143 AGREEMENTS, (2020-2021)
TABLE 144 PARTNERSHIPS, (2020-2021)
TABLE 145 EXPANSION, (2020-2021)
TABLE 146 OTHERS, (2020-2021)
TABLE 147 BAYER GROUP: TOTAL REVENUE AND R&D EXPENSES (2019-2021) (Q3) ($MN)
TABLE 148 BAYER GROUP: TOTAL REVENUE, BY SEGMENTS (2019-2021) (Q3) ($MN)
TABLE 149 BAYER GROUP: TOTAL REVENUE, BY GEOGRAPHY (2019-2021) (Q3) ($MN)
TABLE 150 CARDINAL HEALTH, INC.: TOTAL REVENUE AND R&D EXPENSES (2020-2022) (Q1) ($MN)
TABLE 151 CARDINAL HEALTH, INC.: TOTAL REVENUE, BY SEGMENTS, (2020 -2022) (Q1) ($MN)
TABLE 152 CARDINAL HEALTH, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2019-2021) ($MN)
TABLE 153 FUJIFILM HOLDING CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2019– 2021) (Q2) ($MN)
TABLE 154 FUJIFILM HOLDING CORPORATION: TOTAL REVENUE, BY SEGMENTS (2019-2021) (Q2) ($MN)
TABLE 155 FUJIFILM HOLDING CORPORATION: TOTAL REVENUE, BY GEOGRAPHY (2019 – 2021) (Q2) ($MN)
TABLE 156 GE COMPANY: TOTAL REVENUE AND R&D EXPENSES (2019–2021)(Q3) ($MN)
TABLE 157 GE COMPANY: TOTAL REVENUE, BY SEGMENTS (2019-2021) (Q3) ($MN)
TABLE 158 GE COMPANY: TOTAL REVENUE, BY GEOGRAPHY (2019 –2021) (Q3) ($MN)
TABLE 159 GUERBET: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) (Q3) ($MN)
TABLE 160 GUERBET TOTAL REVENUE, BY SEGMENT (2019-2021) (Q2) ($MN)
TABLE 161 LANTHEUS MEDICAL IMAGING INC.: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) (Q3) ($MN)
TABLE 162 LANTHEUS MEDICAL IMAGING INC.: TOTAL REVENUE, BY PRODUCTS (2019-2021) (Q3) ($MN)
TABLE 163 LANTHEUS MEDICAL IMAGING INC.: TOTAL REVENUE, BY GEOGRAPHY (2019-2021) (Q3)($MN)
TABLE 164 NOVARTIS INTERNATIONAL AG: TOTAL REVENUE AND R&D EXPENSES (2019-2021) (Q3) ($MN)
TABLE 165 NOVARTIS INTERNATIONAL AG: TOTAL REVENUE, BY SEGMENTS (2019-2021) (Q3) ($MN)
TABLE 166 NOVARTIS INTERNATIONAL AG: TOTAL REVENUE, BY GEOGRAPHY (2019-2021) (Q3) ($MN)
TABLE 167 SUMITOMO CHEMICALS: TOTAL REVENUE AND R&D EXPENSES (2019-2021) (Q2) ($MN)
TABLE 168 SUMITOMO CHEMICALS: TOTAL REVENUE, BY SEGMENTS (2019-2021) (Q2) ($MN)
TABLE 169 SUMITOMO CHEMICALS: TOTAL REVENUE, BY GEOGRAPHY (2019-2021) (Q2) ($MN)
TABLE 1 MEDICAL IMAGING AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 2 MEDICAL IMAGING AGENTS CLINICAL TRIALS
TABLE 3 TECHNETIUM (TC-99M) CURRENT IRRADIATORS
TABLE 4 TECHNETIUM (TC-99M) POTENTIAL IRRADIATORS
TABLE 5 TECHNETIUM (TC-99M) POTENTIAL IRRADIATORS
TABLE 6 TECHNETIUM (TC-99M) CURRENT PROCESSORS
TABLE 7 POTENTIAL PROCESSORS ENTERING THE GLOBAL SUPPLY CHAIN
TABLE 8 FDA APPROVED DIAGNOSTIC RADIOPHARMACEUTICALS
TABLE 9 X-RAY/ CT CONTRAST AGENT MEDIATED GLOBAL PROCEDURE VOLUME, (2020-2028) (MN)
TABLE 10 X-RAY/ CT CONTRAST AGENT GLOBAL CONSUMPTION, (2020-2028) (MN L)
TABLE 11 MRI CONTRAST AGENT CONTRAST MEDIATED GLOBAL PROCEDURE VOLUME, (2020-2028) (MN)
TABLE 12 MRI CONTRAST AGENTS GLOBAL CONSUMPTION, (2020-2028) (MN L)
TABLE 13 ULTRASOUND CONTRAST AGENTS MEDIATED PROCEDURE VOLUME, (2020-2028) (MN)
TABLE 14 ULTRASOUND CONTRAST AGENTS GLOBAL CONSUMPTION, (2020-2028) (L)
TABLE 15 MEDICAL IMAGING AGENTS GLOBAL MARKET REVENUE, BASED ON MOLECULE/ISOTOPE, (2020-2028) ($MN)
TABLE 16 CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 17 CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON MOLECULE, (2020-2028) ($MN)
TABLE 18 IODINATED CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 19 IODINATED CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON IONICITY, (2020-2028) ($MN)
TABLE 20 IODINATED IONIC CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 21 IODINATED NON-IONIC CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 22 NON-IONIC CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON CHEMICAL STRUCTURE, (2020-2028) ($MN)
TABLE 23 NON-IONIC MONOMER CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 24 NON-IONIC DIMER CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 25 GADOLINIUM BASED CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON CHEMICAL STRUCTURE, (2020-2028) ($MN)
TABLE 26 GADOLINIUM BASED CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 27 MACROCYCLIC CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 28 MACROCYCLIC CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON IONICITY, (2020-2028) ($MN)
TABLE 29 MACROCYCLIC IONIC CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 30 MACROCYCLIC NON-IONIC CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 31 LINEAR GADOLINIUM BASED CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 32 LINEAR GADOLINIUM BASED CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON IONICITY, (2020-2028) ($MN)
TABLE 33 LINEAR IONIC CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 34 LINEAR NON-IONIC CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 35 MICROBUBBLE CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 36 OTHER CONTRAST AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 37 NUCLEAR IMAGING AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 38 NUCLEAR IMAGING AGENTS GLOBAL MARKET REVENUE, BASED ON ISOTOPE, (2020-2028) ($MN)
TABLE 39 TECHNETIUM (TC-99M) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 40 THALLIUM (TL-201) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 41 GALLIUM (GA-67) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 42 IODINE (I-123) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 43 XENON (XE-133) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 44 RHENIUM (RE-186) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 45 FLUORODEOXYGLUCOSE(18F-FDG) GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 46 GALLIUM (GA-68) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 47 GALLIUM (GA-68) GENERATOR SUPPLIERS AND ITS CHARACTERISTICS
TABLE 48 RUBIDIUM (RB-82) ISOTOPE GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 49 STRONTIUM (SR-82)/RUBIDIUM (RB-82) GENERATOR SUPPLIERS
TABLE 50 OTHER ISOTOPES GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 51 MEDICAL IMAGING AGENTS GLOBAL MARKET REVENUE, BASED ON MODALITY, (2020-2028) ($MN)
TABLE 52 X-RAY/CT MODALITY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 53 MRI MODALITY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 54 ULTRASOUND MODALITY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 55 SPECT MODALITY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 56 PET MODALITY GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 57 MEDICAL IMAGING AGENTS GLOBAL MARKET REVENUE, BASED ON APPLICATION, (2020-2028) ($MN)
TABLE 58 CARDIOVASCULAR APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 59 CANCER APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 60 GASTROINTESTINAL APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 61 MUSCULOSKELETAL APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 62 NEUROLOGY APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 63 NEPHROLOGY APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 64 OBSTETRICS AND GYNECOLOGY APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 65 PULMONARY APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 66 HEPATOLOGY APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 67 OTHER APPLICATIONS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 68 MEDICAL IMAGING AGENTS GLOBAL MARKET REVENUE, BASED ON ROUTE OF ADMINISTRATION, (2020-2028) ($MN)
TABLE 69 INTRAVASCULAR ROUTE OF ADMINISTRATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 70 ORAL ROUTE OF ADMINISTRATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 71 RECTAL ROUTE OF ADMINISTRATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 72 OTHER ROUTE OF ADMINISTRATION GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 73 MEDICAL IMAGING AGENTS GLOBAL MARKET REVENUE, BASED ON IMAGING, (2020-2028) ($MN)
TABLE 74 DIAGNOSTIC IMAGING GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 75 INTERVENTIONAL IMAGING GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 76 MEDICAL IMAGING AGENTS GLOBAL MARKET REVENUE, BASED ON END-USER, (2020-2028) ($MN)
TABLE 77 HOSPITAL GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 78 DIAGNOSTIC & AMBULATORY SURGICAL CENTERS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 79 OTHER END-USER GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 80 MEDICAL IMAGING AGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2020-2028) ($MN)
TABLE 81 NORTH AMERICA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPE, (2020-2028) ($MN)
TABLE 82 NORTH-AMERICA CONTRAST AGENTS MARKET REVENUE, BASED ON MOLECULE, (2020-2028) ($MN)
TABLE 83 NORTH-AMERICA IODINATED CONTRAST AGENTS MARKET REVENUE, BASED ON IONICITY, (2020-2028) ($MN)
TABLE 84 NORTH-AMERICA NON-IONIC CONTRAST AGENTS MARKET REVENUE, BASED ON CHEMICAL STRUCTURE,(2020-2028) ($MN)
TABLE 85 NORTH-AMERICA GADOLINIUM CONTRAST AGENTS MARKET REVENUE, BASED ON CHEMICAL STRUCTURE, (2020-2028) ($MN)
TABLE 86 NORTH-AMERICA MACROCYCLIC CONTRAST AGENTS MARKET REVENUE, BASED ON IONICITY, (2020-2028) ($MN)
TABLE 87 NORTH-AMERICA LINEAR CONTRAST AGENTS MARKET REVENUE, BASED ON IONICITY, (2020-2028) ($MN)
TABLE 88 NORTH-AMERICA NUCLEAR IMAGING AGENTS MARKET REVENUE, BASED ON ISOTOPE, (2020-2028) ($MN)
TABLE 89 NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY, (2020-2028) ($MN)
TABLE 90 NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION, (2020-2028) ($MN)
TABLE 91 NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON ROUTE OF ADMINISTRATION, (2020-2028) ($MN)
TABLE 92 NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING, (2020-2028) ($MN)
TABLE 93 NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON END-USER, (2020-2028) ($MN)
TABLE 94 NORTH AMERICA SPECT, PET, CT MRI AND CYCLOTRONS INSTALLED BASE
TABLE 95 NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON COUNTRY, (2020-2028) ($MN)
TABLE 96 EUROPE MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPE, (2020-2028) ($MN)
TABLE 97 EUROPE CONTRAST AGENTS MARKET REVENUE, BASED ON MOLECULE, (2020-2028) ($MN)
TABLE 98 EUROPE IODINATED CONTRAST AGENTS MARKET REVENUE, BASED ON IONICITY, (2020-2028) ($MN)
TABLE 99 EUROPE NON-IONIC CONTRAST AGENTS MARKET REVENUE, BASED ON CHEMICAL STRUCTURE, (2020-2028) ($MN)
TABLE 100 EUROPE GADOLINIUM BASED CONTRAST AGENTS MARKET REVENUE, BASED ON CHEMICAL STRUCTURE, (2020-2028) ($MN)
TABLE 101 EUROPE MACROCYCLIC CONTRAST AGENTS MARKET REVENUE, BASED ON IONICITY, (2020-2028) ($MN)
TABLE 102 EUROPE LINEAR CONTRAST AGENTS MARKET REVENUE, BASED ON IONICITY, (2020-2028) ($MN)
TABLE 103 EUROPE NUCLEAR IMAGING AGENTS MARKET REVENUE, BASED ON ISOTOPE, (2020-2028) ($MN)
TABLE 104 EUROPE MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY, (2020-2028) ($MN)
TABLE 105 EUROPE MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION, (2020-2028) ($MN)
TABLE 106 EUROPE MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON ROUTE OF ADMINISTRATION, (2020-2028) ($MN)
TABLE 107 EUROPE MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING (2020-2028) ($MN)
TABLE 108 EUROPE MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON END-USER,(2020-2028) ($MN)
TABLE 109 EUROPE SPECT, PET, CT MRI AND CYCLOTRONS INSTALLED BASE
TABLE 110 EUROPE MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON COUNTRY, (2020-2028) ($MN)
TABLE 111 APAC MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPE, (2020-2028) ($MN)
TABLE 112 APAC CONTRAST AGENTS MARKET REVENUE, BASED ON MOLECULE, (2020-2028) ($MN)
TABLE 113 APAC IODINATED CONTRAST AGENTS MARKET REVENUE, BASED ON IONICITY,(2020-2028) ($MN)
TABLE 114 APAC NON-IONIC CONTRAST AGENTS MARKET REVENUE, BASED ON CHEMICAL STRUCTURE, (2020-2028) ($MN)
TABLE 115 APAC GADOLINIUM BASED CONTRAST AGENTS MARKET REVENUE, BASED ON CHEMICAL STRUCTURE, (2020-2028) ($MN)
TABLE 116 APAC MACROCYCLIC CONTRAST AGENTS MARKET REVENUE, BASED ON IONICITY, (2020-2028) ($MN)
TABLE 117 APAC LINEAR CONTRAST AGENTS MARKET REVENUE, BASED ON IONICITY, (2020-2028) ($MN)
TABLE 118 APAC NUCLEAR IMAGING AGENTS MARKET REVENUE, BASED ON ISOTOPE, (2020-2028) ($MN)
TABLE 119 APAC MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY, (2020-2028) ($MN)
TABLE 120 APAC MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION, (2020-2028) ($MN)
TABLE 121 APAC MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON ROUTE OF ADMINISTRATION, (2020-2028) ($MN)
TABLE 122 APAC MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING (2020-2028) ($MN)
TABLE 123 APAC MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON END-USER, (2020-2028) ($MN)
TABLE 124 ASIA-PACIFIC SPECT, PET, CT MRI AND CYCLOTRONS INSTALLED BASE
TABLE 125 APAC MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON COUNTRY, (2020-2028) ($MN)
TABLE 126 ROW MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPE, (2020-2028) ($MN)
TABLE 127 ROW CONTRAST AGENTS MARKET REVENUE, BASED ON MOLECULE, (2020-2028) ($MN)
TABLE 128 ROW IODINATED CONTRAST AGENTS MARKET REVENUE, BASED ON IONICITY, (2020-2028) ($MN)
TABLE 129 ROW NON-IONIC CONTRAST AGENTS MARKET REVENUE, BASED ON CHEMICAL STRUCTURE, (2020-2028) ($MN)
TABLE 130 ROW GADOLINIUM BASED CONTRAST AGENTS MARKET REVENUE, BASED ON CHEMICAL STRUCTURE, (2020-2028) ($MN)
TABLE 131 ROW MACROCYCLIC CONTRAST AGENTS MARKET REVENUE, BASED ON IONICITY, (2020-2028) ($MN)
TABLE 132 ROW LINEAR CONTRAST AGENTS MARKET REVENUE, BASED ON IONICITY, (2020-2028) ($MN)
TABLE 133 ROW NUCLEAR IMAGING AGENTS MARKET REVENUE, BASED ON ISOTOPE, (2020-2028) ($MN)
TABLE 134 ROW MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY, (2020-2028) ($MN)
TABLE 135 ROW MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION, (2020-2028) ($MN)
TABLE 136 ROW MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON ROUTE OF ADMINISTRATION, (2020-2028) ($MN)
TABLE 137 ROW MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING (2020-2028) ($MN)
TABLE 138 ROW MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON END-USER, (2020-2028) ($MN)
TABLE 139 ROW SPECT, PET, CT MRI AND CYCLOTRONS INSTALLED BASE
TABLE 140 ROW MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON COUNTRY, (2020-2028) ($MN)
TABLE 141 APPROVALS (2020-2021)
TABLE 142 ACQUISITIONS, (2020-2021)
TABLE 143 AGREEMENTS, (2020-2021)
TABLE 144 PARTNERSHIPS, (2020-2021)
TABLE 145 EXPANSION, (2020-2021)
TABLE 146 OTHERS, (2020-2021)
TABLE 147 BAYER GROUP: TOTAL REVENUE AND R&D EXPENSES (2019-2021) (Q3) ($MN)
TABLE 148 BAYER GROUP: TOTAL REVENUE, BY SEGMENTS (2019-2021) (Q3) ($MN)
TABLE 149 BAYER GROUP: TOTAL REVENUE, BY GEOGRAPHY (2019-2021) (Q3) ($MN)
TABLE 150 CARDINAL HEALTH, INC.: TOTAL REVENUE AND R&D EXPENSES (2020-2022) (Q1) ($MN)
TABLE 151 CARDINAL HEALTH, INC.: TOTAL REVENUE, BY SEGMENTS, (2020 -2022) (Q1) ($MN)
TABLE 152 CARDINAL HEALTH, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2019-2021) ($MN)
TABLE 153 FUJIFILM HOLDING CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2019– 2021) (Q2) ($MN)
TABLE 154 FUJIFILM HOLDING CORPORATION: TOTAL REVENUE, BY SEGMENTS (2019-2021) (Q2) ($MN)
TABLE 155 FUJIFILM HOLDING CORPORATION: TOTAL REVENUE, BY GEOGRAPHY (2019 – 2021) (Q2) ($MN)
TABLE 156 GE COMPANY: TOTAL REVENUE AND R&D EXPENSES (2019–2021)(Q3) ($MN)
TABLE 157 GE COMPANY: TOTAL REVENUE, BY SEGMENTS (2019-2021) (Q3) ($MN)
TABLE 158 GE COMPANY: TOTAL REVENUE, BY GEOGRAPHY (2019 –2021) (Q3) ($MN)
TABLE 159 GUERBET: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) (Q3) ($MN)
TABLE 160 GUERBET TOTAL REVENUE, BY SEGMENT (2019-2021) (Q2) ($MN)
TABLE 161 LANTHEUS MEDICAL IMAGING INC.: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) (Q3) ($MN)
TABLE 162 LANTHEUS MEDICAL IMAGING INC.: TOTAL REVENUE, BY PRODUCTS (2019-2021) (Q3) ($MN)
TABLE 163 LANTHEUS MEDICAL IMAGING INC.: TOTAL REVENUE, BY GEOGRAPHY (2019-2021) (Q3)($MN)
TABLE 164 NOVARTIS INTERNATIONAL AG: TOTAL REVENUE AND R&D EXPENSES (2019-2021) (Q3) ($MN)
TABLE 165 NOVARTIS INTERNATIONAL AG: TOTAL REVENUE, BY SEGMENTS (2019-2021) (Q3) ($MN)
TABLE 166 NOVARTIS INTERNATIONAL AG: TOTAL REVENUE, BY GEOGRAPHY (2019-2021) (Q3) ($MN)
TABLE 167 SUMITOMO CHEMICALS: TOTAL REVENUE AND R&D EXPENSES (2019-2021) (Q2) ($MN)
TABLE 168 SUMITOMO CHEMICALS: TOTAL REVENUE, BY SEGMENTS (2019-2021) (Q2) ($MN)
TABLE 169 SUMITOMO CHEMICALS: TOTAL REVENUE, BY GEOGRAPHY (2019-2021) (Q2) ($MN)
LIST OF FIGURES
FIGURE 1 MEDICAL IMAGING AGENTS GLOBAL MARKET REVENUE AND SHARE, BASED ON REGION, (2020-2028) ($MN) (2021)(%)
FIGURE 2 RESEARCH METHODOLOGY: MEDICAL IMAGING AGENTS GLOBAL MARKET
FIGURE 3 MEDICAL IMAGING AGENTS GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
FIGURE 4 MEDICAL IMAGING AGENTS GLOBAL MARKET: FORECASTING MODEL
FIGURE 5 MEDICAL IMAGING AGENTS GLOBAL MARKET: MARKET CRACKDOWN AND DATA TRIANGULATION
FIGURE 6 MEDICAL IMAGING AGENTS GLOBAL MARKET: MARKET SEGMENTATION
FIGURE 7 MARKET DYNAMICS
FIGURE 8 CONTRAST AGENTS CLINICAL TRIALS BASED ON PHASES
FIGURE 9 CONTRAST AGENTS CLINICAL TRIALS BASED ON APPLICATION
FIGURE 10 NUCLEAR IMAGING AGENTS CLINICAL TRIALS BASED ON PHASE
FIGURE 11 NUCLEAR IMAGING AGENTS CLINICAL TRIALS BASED ON APPLICATION
FIGURE 12 MEDICAL IMAGING AGENTS CLINICAL TRIALS BASED ON MODALITY
FIGURE 13 TECHNETIUM-99M: SUPPLY CHAIN ANALYSIS
FIGURE 14 CONTRAST AGENTS GLOBAL MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 15 MEDICAL IMAGING AGENTS GLOBAL MARKET: PORTER’S ANALYSIS
FIGURE 16 MEDICAL IMAGING AGENTS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2021 (%)
FIGURE 17 MRI GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2021 (%)
FIGURE 18 X-RAY/CT AGENTS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2021 (%)
FIGURE 19 ULTRASOUND AGENTS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2021 (%)
FIGURE 20 SPECT AGENTS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2021 (%)
FIGURE 21 PET AGENTS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2021 (%)
FIGURE 22 REGIONAL AND COUNTRYWISE CONTRAST AGENTS MEDIATED X-RAY/CT PROCEDURE VOLUME (2021) (NO’S)
FIGURE 23 GLOBAL CT/X-RAY NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE (2021) ($MN)
FIGURE 24 NORTH AMERICA CT/X-RAY NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE, (2021) ($MN)
FIGURE 25 EUROPE CT/X-RAY NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE, (2021) ($MN)
FIGURE 26 ASIA – PACIFIC CT/X-RAY NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE, (2021) ($MN)
FIGURE 27 ROW CT/ X-RAY PENETRATION, NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE, (2021) ($MN)
FIGURE 28 REGIONAL AND COUNTRYWISE CONTRAST AGENTS MEDIATED MRI PROCEDURE VOLUME (2021) (NO’S)
FIGURE 29 GLOBAL MRI NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE, (2021) ($MN)
FIGURE 30 NORTH AMERICA MRI NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE, (2021) ($MN)
FIGURE 31 EUROPE MRI NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED MARKET SIZE, (2021) ($MN)
FIGURE 32 ASIA – PACIFIC MRI NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE, (2021) ($MN)
FIGURE 33 ROW MRI NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE, (2021) ($MN)
FIGURE 34 REGIONAL AND COUNTRYWISE CONTRAST AGENTS MEDIATED ULTRASOUND IMAGING PROCEDURE VOLUME (2021) (NO’S)
FIGURE 35 MEDICAL IMAGING AGENTS GLOBAL MARKET SHARE, BASED ON MOLECULE/ISOTOPE (2021 V/S 2028) (%)
FIGURE 36 CONTRAST AGENTS GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
FIGURE 37 CONTRAST AGENTS GLOBAL MARKET SHARE, BASED ON MOLECULE (2021 V/S 2028) (%)
FIGURE 38 IODINATED CONTRAST AGENTS GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
FIGURE 39 IODINATED CONTRAST AGENTS GLOBAL MARKET SHARE, BASED ON IONICITY (2021 V/S 2028) (%)
FIGURE 40 IODINATED IONIC CONTRAST AGENTS GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
FIGURE 41 IODINATED NON-IONIC CONTRAST AGENTS GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
FIGURE 42 NON-IONIC CONTRAST AGENTS GLOBAL MARKET SHARE, BASED ON CHEMICAL STRUCTURE (2021 V/S 2028) (%)
FIGURE 43 NON-IONIC MONOMER CONTRAST AGENTS MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
FIGURE 44 GADOLINIUM BASED CONTRAST AGENTS GLOBAL MARKET SHARE, BASED ON CHEMICAL STRUCTURE (2021 V/S 2028) (%)
FIGURE 45 MACROCYCLIC CONTRAST AGENTS GLOBAL MARKET SHARE, BASED ON IONICITY (2021 V/S 2028) (%)
FIGURE 46 NUCLEAR IMAGING AGENTS GLOBAL MARKET SHARE, BASED ON ISOTOPE (2021 V/S 2028) (%)
FIGURE 47 THALLIUM (TL-201) ISOTOPE GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
FIGURE 48 IODINE (I-123) ISOTOPE GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
FIGURE 49 IODINE (I-123) SUPPLY CHAIN
FIGURE 50 XENON (XE-133) ISOTOPE GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
FIGURE 51 RHENIUM (RE-186) ISOTOPE GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
FIGURE 52 FLUORINE-18 (F-18) SUPPLY CHAIN
FIGURE 53 SUPPLY CHAIN OF GE-68/GA-68 GENERATOR
FIGURE 54 MEDICAL IMAGING AGENTS GLOBAL MARKET SHARE, BASED ON MODALITY (2021 V/S 2028) (%)
FIGURE 55 MEDICAL IMAGING AGENTS GLOBAL MARKET SHARE, BASED ON APPLICATION (2021) (%)
FIGURE 56 CARDIOVASCULAR APPLICATION GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
FIGURE 57 GASTROINTESTINAL APPLICATION GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
FIGURE 58 MUSCULOSKELETAL APPLICATION GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
FIGURE 59 NEPHROLOGY APPLICATION GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
FIGURE 60 OBSTETRICS AND GYNECOLOGY APPLICATION GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
FIGURE 61 MEDICAL IMAGING AGENTS GLOBAL MARKET SHARE, BASED ON ROUTE OF ADMINISTRATION (2021 V/S 2028) (%)
FIGURE 62 ORAL ROUTE OF ADMINISTRATION GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
FIGURE 63 RECTAL ROUTE OF ADMINISTRATION GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
FIGURE 64 OTHER ROUTE OF ADMINISTRATION GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
FIGURE 65 MEDICAL IMAGING AGENTS GLOBAL MARKET SHARE, BASED ON IMAGING (2021 V/S 2028) (%)
FIGURE 66 MEDICAL IMAGING AGENTS GLOBAL MARKET SHARE, BASED ON END-USER (2021 V/S 2028) (%)
FIGURE 67 HOSPITAL END-USER GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
FIGURE 68 MEDICAL IMAGING AGENTS GLOBAL MARKET REVENUE, BASED ON REGION (2020-2028) ($MN) & CAGR (%)
FIGURE 69 NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON MOLECULE/ISOTOPE (2021 V/S 2028) (%)
FIGURE 70 NORTH-AMERICA CONTRAST AGENTS MARKET SHARE, BASED ON MOLECULE (2021 V/S 2028) (%)
FIGURE 71 NORTH-AMERICA NON-IONIC CONTRAST AGENTS MARKET SHARE, BASED ON CHEMICAL STRUCTURE (2021 V/S 2028) (%)
FIGURE 72 NORTH-AMERICA MACROCYCLIC AGENTS MARKET SHARE, BASED ON IONICITY (2021 V/S 2028) (%)
FIGURE 73 NORTH-AMERICA NUCLEAR IMAGING AGENTS MARKET SHARE, BASED ON ISOTOPE (2021 V/S 2028) (%)
FIGURE 74 NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON MODALITY (2021 V/S 2028) (%)
FIGURE 75 NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON APPLICATION (2021) (%)
FIGURE 76 NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON ROUTE OF ADMINISTRATION (2021 V/S 2028) (%)
FIGURE 77 NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON IMAGING (2021 V/S 2028) (%)
FIGURE 78 NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON END-USER (2021 V/S 2028) (%)
FIGURE 79 NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON COUNTRY (2021 V/S 2028) (%)
FIGURE 80 U.S. MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPES & CONTRAST AGENTS BASED ON MOLECULE (2021) ($MN)
FIGURE 81 U.S. MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY & ROUTE OF ADMINISTRATION (2021 V/S 2028) ($MN)
FIGURE 82 U.S. MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION (2021 V/S 2028) ($MN)
FIGURE 83 U.S. MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING & ROUTE OF ADMINISTRATION (2021 V/S 2028) ($MN)
FIGURE 84 REST OF N.A. MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPES & CONTRAST AGENTS BY MOLECULE (2021) ($MN)
FIGURE 85 REST OF N.A. MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY & ROUTE OF ADMINISTRATION (2021 V/S 2028) ($MN)
FIGURE 86 REST OF N.A. MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION (2021 V/S 2028) ($MN)
FIGURE 87 REST OF N.A. MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING AND ROUTE OF ADMINISTRATION (2021 V/S 2028) ($MN)
FIGURE 88 EUROPE MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON MOLECULE/ISOTOPE (2021 V/S 2028) (%)
FIGURE 89 EUROPE MEDICAL CONTRAST AGENTS MARKET SHARE, BASED ON MOLECULE (2021 V/S 2028) (%)
FIGURE 90 EUROPE IODINATED CONTRAST AGENTS MARKET SHARE, BASED ON IONICITY (2021 V/S 2028) (%)
FIGURE 91 EUROPE NON-IONIC CONTRAST AGENTS MARKET SHARE, BASED ON CHEMICAL STRUCTURE (2021 V/S 2028) (%)
FIGURE 92 EUROPE MACROCYCLIC CONTRAST AGENTS MARKET SHARE, BASED ON IONICITY (2021 V/S 2028) (%)
FIGURE 93 EUROPE NUCLEAR IMAGING AGENTS MARKET SHARE, BASED ON ISOTOPE (2021 V/S 2028) (%)
FIGURE 94 EUROPE MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON MODALITY (2021 V/S 2028) (%)
FIGURE 95 EUROPE MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON APPLICATION (2021) (%)
FIGURE 96 EUROPE MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON ROUTE OF ADMINISTRATION (2021 V/S 2028) (%)
FIGURE 97 EUROPE MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON IMAGING (2021 V/S 2028) (%)
FIGURE 98 EUROPE MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON END-USER (2021 V/S 2028) (%)
FIGURE 99 EUROPE MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON COUNTRY (2021 V/S 2028) (%)
FIGURE 100 GERMANY MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPE & CONTRAST AGENTS BASED ON MOLECULE (2021) ($MN)
FIGURE 101 GERMANY MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY AND ROUTE OF ADMINISTRATION (2021 V/S 2028) ($MN)
FIGURE 102 GERMANY MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION (2021 V/S 2028) ($MN)
FIGURE 103 GERMANY MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING AND END USER (2021 V/S 2028) ($MN)
FIGURE 104 FRANCE MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPE & CONTRAST AGENTS BASED ON MOLECULE(2021) ($MN)
FIGURE 105 FRANCE MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY AND ROUTE OF ADMINISTRATION (2021 V/S 2028) ($MN)
FIGURE 106 FRANCE MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION (2021 V/S 2028) ($MN)
FIGURE 107 FRANCE MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING & END USERS (2021 V/S 2028) ($MN)
FIGURE 108 ITALY MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPE & CONTRAST AGENTS BY MOLECULE (2021) ($MN)
FIGURE 109 ITALY MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY AND ROUTE OF ADMINISTRATION (2021 V/S 2028) ($MN)
FIGURE 110 ITALY MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION (2021 V/S 2028) ($MN)
FIGURE 111 ITALY MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING & END USERS (2021 V/S 2028) ($MN)
FIGURE 112 REST OF E.U. MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPES & CONTRAST AGENTS BASED ON MOLECULE (2021) ($MN)
FIGURE 113 REST OF E.U. MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY & ROUTE OF ADMINISTRATION(2021 V/S 2028) ($MN)
FIGURE 114 REST OF E.U. MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION (2021 V/S 2028) ($MN)
FIGURE 115 REST OF E.U. MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING & ROUTE OF ADMINISTRATION (2021 V/S 2028) ($MN)
FIGURE 116 APAC MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON MOLECULE/ISOTOPE (2021 V/S 2028) (%)
FIGURE 117 APAC CONTRAST AGENTS MARKET SHARE, BASED ON MOLECULE (2021 V/S 2028) (%)
FIGURE 118 APAC NON-IONIC CONTRAST AGENTS MARKET SHARE, BASED ON CHEMICAL STRUCTURE (2021 V/S 2028) (%)
FIGURE 119 APAC MACROCYCLIC CONSTRAST AGENTS MARKET SHARE, BASED ON IONICITY (2021 V/S 2028) (%)
FIGURE 120 APAC NUCLEAR IMAGING AGENTS MARKET SHARE, BASED ON ISOTOPE (2021 V/S 2028) (%)
FIGURE 121 APAC MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON MODALITY (2021 V/S 2028) (%)
FIGURE 122 APAC MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON APPLICATION (2021) (%)
FIGURE 123 APAC MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON ROUTE OF ADMINISTRATION (2021 V/S 2028) (%)
FIGURE 124 APAC MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON IMAGING (2021 V/S 2028) (%)
FIGURE 125 APAC MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON END-USER (2021 V/S 2028) (%)
FIGURE 126 APAC MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON COUNTRY (2021 V/S 2028) (%)
FIGURE 127 CHINA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPE & CONTRAST AGENTS BY MOLECULE (2021) ($MN)
FIGURE 128 CHINA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY AND ROUTE OF ADMINISTRATION (2021 V/S 2028) ($MN)
FIGURE 129 CHINA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION (2021 V/S 2028) ($MN)
FIGURE 130 CHINA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING AND END USERS (2021 V/S 2028) ($MN)
FIGURE 131 JAPAN MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPE & CONTRAST AGENTS BY MOLECULE (2021) ($MN)
FIGURE 132 JAPAN MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY & ROUTE OF ADMINISTRATION BY MOLECULE (2021 V/S 2028) ($MN)
FIGURE 133 JAPAN MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION (2021 V/S 2028) ($MN)
FIGURE 134 JAPAN MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING AND END USERS (2021 V/S 2028) ($MN)
FIGURE 135 SOUTH KOREA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE & CONTRAST AGENTS BASED ON MOLECULE (2021) ($MN)
FIGURE 136 SOUTH KOREA NUCLEAR IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY & ROUTE OF ADMINISTRATION (2021 V/S 2028) ($MN)
FIGURE 137 SOUTH KOREA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION (2021 V/S 2028) ($MN)
FIGURE 138 SOUTH KOREA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING & END USERS (2021 V/S 2028) ($MN)
FIGURE 139 REST OF APAC MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPE & CONTRAST AGENTS BASED ON MOLECULE (2021) ($MN)
FIGURE 140 REST OF APAC CONTRAST AGENTS MARKET REVENUE, BASED ON MODALITY & ROUTE OF ADMINISTRATION (2021 V/S 2028) ($MN)
FIGURE 141 SOUTH KOREA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION (2021 V/S 2028) ($MN)
FIGURE 142 SOUTH KOREA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING & END USERS (2021 V/S 2028) ($MN)
FIGURE 143 ROW MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON MOLECULE/ISOTOPE (2021 V/S 2028) (%)
FIGURE 144 ROW CONTRAST AGENTS MARKET SHARE, BASED ON MOLECULE (2021 V/S 2028) (%)
FIGURE 145 ROW NON-IONIC CONTRAST AGENTS MARKET SHARE, BASED ON CHEMICAL STRUCTURE (2021 V/S 2028) (%)
FIGURE 146 ROW MACROCYCLIC AGENTS MARKET SHARE, BASED ON IONICITY (2021 V/S 2028) (%)
FIGURE 147 ROW NUCLEAR IMAGING AGENTS MARKET SHARE, BASED ON ISOTOPE (2021 V/S 2028) (%)
FIGURE 148 ROW MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON MODALITY (2021 V/S 2028) (%)
FIGURE 149 ROW MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON APPLICATION (2021) (%)
FIGURE 150 ROW MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON ROUTE OF ADMINISTRATION (2021 V/S 2028) (%)
FIGURE 151 ROW MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON IMAGING (2021 V/S 2028) (%)
FIGURE 152 ROW MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON END-USER (2021 V/S 2028) (%)
FIGURE 153 ROW MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON COUNTRY (2021 V/S 2028) (%)
FIGURE 154 TURKEY MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPE & CONTRAST AGENTS BASED ON MOLECULE (2021) ($MN)
FIGURE 155 TURKEY MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY AND ROUTE OF ADMINISTRATION (2021 V/S 2028) ($MN)
FIGURE 156 TURKEY MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION (2021 V/S 2028) ($MN)
FIGURE 157 TURKEY MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING AND END USERS (2021 V/S 2028) ($MN)
FIGURE 158 BRAZIL MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPE & CONTRAST AGENTS BASED ON MOLECULE (2021) ($MN)
FIGURE 159 BRAZIL MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY AND ROUTE OF ADMINISTRATION (2021 V/S 2028) ($MN)
FIGURE 160 BRAZIL MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION (2021 V/S 2028) ($MN)
FIGURE 161 BRAZIL MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING AND END USERS (2021 V/S 2028) ($MN)
FIGURE 162 OTHERS MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPE & CONTRAST AGENTS BASED ON MOLECULE (2021) ($MN)
FIGURE 163 OTHERS MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY AND ROUTE OF ADMINISTRATION (2021 V/S 2028) ($MN)
FIGURE 164 OTHERS MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION (2021 V/S 2028) ($MN)
FIGURE 165 OTHERS MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING AND END USERS (2021 V/S 2028) ($MN)
FIGURE 166 KEY GROWTH STRATEGIES (2020–2021)
FIGURE 167 SWOT: BAYER GROUP
FIGURE 168 SWOT: BRACCO GROUP
FIGURE 169 SWOT: CARDINAL HEALTH, INC
FIGURE 170 SWOT: CURIUM PHARMA
FIGURE 171 SWOT: FUJIFILM HOLDING CORPORATION
FIGURE 172 SWOT: GE HEALTHCARE
FIGURE 173 SWOT: GUERBET
FIGURE 174 SWOT: LANTHEUS MEDICAL IMAGING INC.
FIGURE 175 SWOT: NOVARTIS INTERNATIONAL AG
FIGURE 176 SWOT: SUMITOMO CHEMICALS
FIGURE 1 MEDICAL IMAGING AGENTS GLOBAL MARKET REVENUE AND SHARE, BASED ON REGION, (2020-2028) ($MN) (2021)(%)
FIGURE 2 RESEARCH METHODOLOGY: MEDICAL IMAGING AGENTS GLOBAL MARKET
FIGURE 3 MEDICAL IMAGING AGENTS GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
FIGURE 4 MEDICAL IMAGING AGENTS GLOBAL MARKET: FORECASTING MODEL
FIGURE 5 MEDICAL IMAGING AGENTS GLOBAL MARKET: MARKET CRACKDOWN AND DATA TRIANGULATION
FIGURE 6 MEDICAL IMAGING AGENTS GLOBAL MARKET: MARKET SEGMENTATION
FIGURE 7 MARKET DYNAMICS
FIGURE 8 CONTRAST AGENTS CLINICAL TRIALS BASED ON PHASES
FIGURE 9 CONTRAST AGENTS CLINICAL TRIALS BASED ON APPLICATION
FIGURE 10 NUCLEAR IMAGING AGENTS CLINICAL TRIALS BASED ON PHASE
FIGURE 11 NUCLEAR IMAGING AGENTS CLINICAL TRIALS BASED ON APPLICATION
FIGURE 12 MEDICAL IMAGING AGENTS CLINICAL TRIALS BASED ON MODALITY
FIGURE 13 TECHNETIUM-99M: SUPPLY CHAIN ANALYSIS
FIGURE 14 CONTRAST AGENTS GLOBAL MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 15 MEDICAL IMAGING AGENTS GLOBAL MARKET: PORTER’S ANALYSIS
FIGURE 16 MEDICAL IMAGING AGENTS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2021 (%)
FIGURE 17 MRI GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2021 (%)
FIGURE 18 X-RAY/CT AGENTS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2021 (%)
FIGURE 19 ULTRASOUND AGENTS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2021 (%)
FIGURE 20 SPECT AGENTS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2021 (%)
FIGURE 21 PET AGENTS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2021 (%)
FIGURE 22 REGIONAL AND COUNTRYWISE CONTRAST AGENTS MEDIATED X-RAY/CT PROCEDURE VOLUME (2021) (NO’S)
FIGURE 23 GLOBAL CT/X-RAY NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE (2021) ($MN)
FIGURE 24 NORTH AMERICA CT/X-RAY NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE, (2021) ($MN)
FIGURE 25 EUROPE CT/X-RAY NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE, (2021) ($MN)
FIGURE 26 ASIA – PACIFIC CT/X-RAY NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE, (2021) ($MN)
FIGURE 27 ROW CT/ X-RAY PENETRATION, NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE, (2021) ($MN)
FIGURE 28 REGIONAL AND COUNTRYWISE CONTRAST AGENTS MEDIATED MRI PROCEDURE VOLUME (2021) (NO’S)
FIGURE 29 GLOBAL MRI NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE, (2021) ($MN)
FIGURE 30 NORTH AMERICA MRI NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE, (2021) ($MN)
FIGURE 31 EUROPE MRI NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED MARKET SIZE, (2021) ($MN)
FIGURE 32 ASIA – PACIFIC MRI NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE, (2021) ($MN)
FIGURE 33 ROW MRI NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE, (2021) ($MN)
FIGURE 34 REGIONAL AND COUNTRYWISE CONTRAST AGENTS MEDIATED ULTRASOUND IMAGING PROCEDURE VOLUME (2021) (NO’S)
FIGURE 35 MEDICAL IMAGING AGENTS GLOBAL MARKET SHARE, BASED ON MOLECULE/ISOTOPE (2021 V/S 2028) (%)
FIGURE 36 CONTRAST AGENTS GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
FIGURE 37 CONTRAST AGENTS GLOBAL MARKET SHARE, BASED ON MOLECULE (2021 V/S 2028) (%)
FIGURE 38 IODINATED CONTRAST AGENTS GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
FIGURE 39 IODINATED CONTRAST AGENTS GLOBAL MARKET SHARE, BASED ON IONICITY (2021 V/S 2028) (%)
FIGURE 40 IODINATED IONIC CONTRAST AGENTS GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
FIGURE 41 IODINATED NON-IONIC CONTRAST AGENTS GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
FIGURE 42 NON-IONIC CONTRAST AGENTS GLOBAL MARKET SHARE, BASED ON CHEMICAL STRUCTURE (2021 V/S 2028) (%)
FIGURE 43 NON-IONIC MONOMER CONTRAST AGENTS MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
FIGURE 44 GADOLINIUM BASED CONTRAST AGENTS GLOBAL MARKET SHARE, BASED ON CHEMICAL STRUCTURE (2021 V/S 2028) (%)
FIGURE 45 MACROCYCLIC CONTRAST AGENTS GLOBAL MARKET SHARE, BASED ON IONICITY (2021 V/S 2028) (%)
FIGURE 46 NUCLEAR IMAGING AGENTS GLOBAL MARKET SHARE, BASED ON ISOTOPE (2021 V/S 2028) (%)
FIGURE 47 THALLIUM (TL-201) ISOTOPE GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
FIGURE 48 IODINE (I-123) ISOTOPE GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
FIGURE 49 IODINE (I-123) SUPPLY CHAIN
FIGURE 50 XENON (XE-133) ISOTOPE GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
FIGURE 51 RHENIUM (RE-186) ISOTOPE GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
FIGURE 52 FLUORINE-18 (F-18) SUPPLY CHAIN
FIGURE 53 SUPPLY CHAIN OF GE-68/GA-68 GENERATOR
FIGURE 54 MEDICAL IMAGING AGENTS GLOBAL MARKET SHARE, BASED ON MODALITY (2021 V/S 2028) (%)
FIGURE 55 MEDICAL IMAGING AGENTS GLOBAL MARKET SHARE, BASED ON APPLICATION (2021) (%)
FIGURE 56 CARDIOVASCULAR APPLICATION GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
FIGURE 57 GASTROINTESTINAL APPLICATION GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
FIGURE 58 MUSCULOSKELETAL APPLICATION GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
FIGURE 59 NEPHROLOGY APPLICATION GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
FIGURE 60 OBSTETRICS AND GYNECOLOGY APPLICATION GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
FIGURE 61 MEDICAL IMAGING AGENTS GLOBAL MARKET SHARE, BASED ON ROUTE OF ADMINISTRATION (2021 V/S 2028) (%)
FIGURE 62 ORAL ROUTE OF ADMINISTRATION GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
FIGURE 63 RECTAL ROUTE OF ADMINISTRATION GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
FIGURE 64 OTHER ROUTE OF ADMINISTRATION GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
FIGURE 65 MEDICAL IMAGING AGENTS GLOBAL MARKET SHARE, BASED ON IMAGING (2021 V/S 2028) (%)
FIGURE 66 MEDICAL IMAGING AGENTS GLOBAL MARKET SHARE, BASED ON END-USER (2021 V/S 2028) (%)
FIGURE 67 HOSPITAL END-USER GLOBAL MARKET SHARE, BASED ON REGION (2021 V/S 2028) (%)
FIGURE 68 MEDICAL IMAGING AGENTS GLOBAL MARKET REVENUE, BASED ON REGION (2020-2028) ($MN) & CAGR (%)
FIGURE 69 NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON MOLECULE/ISOTOPE (2021 V/S 2028) (%)
FIGURE 70 NORTH-AMERICA CONTRAST AGENTS MARKET SHARE, BASED ON MOLECULE (2021 V/S 2028) (%)
FIGURE 71 NORTH-AMERICA NON-IONIC CONTRAST AGENTS MARKET SHARE, BASED ON CHEMICAL STRUCTURE (2021 V/S 2028) (%)
FIGURE 72 NORTH-AMERICA MACROCYCLIC AGENTS MARKET SHARE, BASED ON IONICITY (2021 V/S 2028) (%)
FIGURE 73 NORTH-AMERICA NUCLEAR IMAGING AGENTS MARKET SHARE, BASED ON ISOTOPE (2021 V/S 2028) (%)
FIGURE 74 NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON MODALITY (2021 V/S 2028) (%)
FIGURE 75 NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON APPLICATION (2021) (%)
FIGURE 76 NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON ROUTE OF ADMINISTRATION (2021 V/S 2028) (%)
FIGURE 77 NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON IMAGING (2021 V/S 2028) (%)
FIGURE 78 NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON END-USER (2021 V/S 2028) (%)
FIGURE 79 NORTH-AMERICA MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON COUNTRY (2021 V/S 2028) (%)
FIGURE 80 U.S. MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPES & CONTRAST AGENTS BASED ON MOLECULE (2021) ($MN)
FIGURE 81 U.S. MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY & ROUTE OF ADMINISTRATION (2021 V/S 2028) ($MN)
FIGURE 82 U.S. MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION (2021 V/S 2028) ($MN)
FIGURE 83 U.S. MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING & ROUTE OF ADMINISTRATION (2021 V/S 2028) ($MN)
FIGURE 84 REST OF N.A. MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPES & CONTRAST AGENTS BY MOLECULE (2021) ($MN)
FIGURE 85 REST OF N.A. MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY & ROUTE OF ADMINISTRATION (2021 V/S 2028) ($MN)
FIGURE 86 REST OF N.A. MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION (2021 V/S 2028) ($MN)
FIGURE 87 REST OF N.A. MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING AND ROUTE OF ADMINISTRATION (2021 V/S 2028) ($MN)
FIGURE 88 EUROPE MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON MOLECULE/ISOTOPE (2021 V/S 2028) (%)
FIGURE 89 EUROPE MEDICAL CONTRAST AGENTS MARKET SHARE, BASED ON MOLECULE (2021 V/S 2028) (%)
FIGURE 90 EUROPE IODINATED CONTRAST AGENTS MARKET SHARE, BASED ON IONICITY (2021 V/S 2028) (%)
FIGURE 91 EUROPE NON-IONIC CONTRAST AGENTS MARKET SHARE, BASED ON CHEMICAL STRUCTURE (2021 V/S 2028) (%)
FIGURE 92 EUROPE MACROCYCLIC CONTRAST AGENTS MARKET SHARE, BASED ON IONICITY (2021 V/S 2028) (%)
FIGURE 93 EUROPE NUCLEAR IMAGING AGENTS MARKET SHARE, BASED ON ISOTOPE (2021 V/S 2028) (%)
FIGURE 94 EUROPE MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON MODALITY (2021 V/S 2028) (%)
FIGURE 95 EUROPE MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON APPLICATION (2021) (%)
FIGURE 96 EUROPE MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON ROUTE OF ADMINISTRATION (2021 V/S 2028) (%)
FIGURE 97 EUROPE MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON IMAGING (2021 V/S 2028) (%)
FIGURE 98 EUROPE MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON END-USER (2021 V/S 2028) (%)
FIGURE 99 EUROPE MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON COUNTRY (2021 V/S 2028) (%)
FIGURE 100 GERMANY MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPE & CONTRAST AGENTS BASED ON MOLECULE (2021) ($MN)
FIGURE 101 GERMANY MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY AND ROUTE OF ADMINISTRATION (2021 V/S 2028) ($MN)
FIGURE 102 GERMANY MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION (2021 V/S 2028) ($MN)
FIGURE 103 GERMANY MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING AND END USER (2021 V/S 2028) ($MN)
FIGURE 104 FRANCE MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPE & CONTRAST AGENTS BASED ON MOLECULE(2021) ($MN)
FIGURE 105 FRANCE MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY AND ROUTE OF ADMINISTRATION (2021 V/S 2028) ($MN)
FIGURE 106 FRANCE MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION (2021 V/S 2028) ($MN)
FIGURE 107 FRANCE MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING & END USERS (2021 V/S 2028) ($MN)
FIGURE 108 ITALY MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPE & CONTRAST AGENTS BY MOLECULE (2021) ($MN)
FIGURE 109 ITALY MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY AND ROUTE OF ADMINISTRATION (2021 V/S 2028) ($MN)
FIGURE 110 ITALY MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION (2021 V/S 2028) ($MN)
FIGURE 111 ITALY MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING & END USERS (2021 V/S 2028) ($MN)
FIGURE 112 REST OF E.U. MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPES & CONTRAST AGENTS BASED ON MOLECULE (2021) ($MN)
FIGURE 113 REST OF E.U. MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY & ROUTE OF ADMINISTRATION(2021 V/S 2028) ($MN)
FIGURE 114 REST OF E.U. MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION (2021 V/S 2028) ($MN)
FIGURE 115 REST OF E.U. MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING & ROUTE OF ADMINISTRATION (2021 V/S 2028) ($MN)
FIGURE 116 APAC MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON MOLECULE/ISOTOPE (2021 V/S 2028) (%)
FIGURE 117 APAC CONTRAST AGENTS MARKET SHARE, BASED ON MOLECULE (2021 V/S 2028) (%)
FIGURE 118 APAC NON-IONIC CONTRAST AGENTS MARKET SHARE, BASED ON CHEMICAL STRUCTURE (2021 V/S 2028) (%)
FIGURE 119 APAC MACROCYCLIC CONSTRAST AGENTS MARKET SHARE, BASED ON IONICITY (2021 V/S 2028) (%)
FIGURE 120 APAC NUCLEAR IMAGING AGENTS MARKET SHARE, BASED ON ISOTOPE (2021 V/S 2028) (%)
FIGURE 121 APAC MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON MODALITY (2021 V/S 2028) (%)
FIGURE 122 APAC MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON APPLICATION (2021) (%)
FIGURE 123 APAC MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON ROUTE OF ADMINISTRATION (2021 V/S 2028) (%)
FIGURE 124 APAC MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON IMAGING (2021 V/S 2028) (%)
FIGURE 125 APAC MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON END-USER (2021 V/S 2028) (%)
FIGURE 126 APAC MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON COUNTRY (2021 V/S 2028) (%)
FIGURE 127 CHINA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPE & CONTRAST AGENTS BY MOLECULE (2021) ($MN)
FIGURE 128 CHINA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY AND ROUTE OF ADMINISTRATION (2021 V/S 2028) ($MN)
FIGURE 129 CHINA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION (2021 V/S 2028) ($MN)
FIGURE 130 CHINA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING AND END USERS (2021 V/S 2028) ($MN)
FIGURE 131 JAPAN MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPE & CONTRAST AGENTS BY MOLECULE (2021) ($MN)
FIGURE 132 JAPAN MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY & ROUTE OF ADMINISTRATION BY MOLECULE (2021 V/S 2028) ($MN)
FIGURE 133 JAPAN MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION (2021 V/S 2028) ($MN)
FIGURE 134 JAPAN MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING AND END USERS (2021 V/S 2028) ($MN)
FIGURE 135 SOUTH KOREA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE & CONTRAST AGENTS BASED ON MOLECULE (2021) ($MN)
FIGURE 136 SOUTH KOREA NUCLEAR IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY & ROUTE OF ADMINISTRATION (2021 V/S 2028) ($MN)
FIGURE 137 SOUTH KOREA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION (2021 V/S 2028) ($MN)
FIGURE 138 SOUTH KOREA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING & END USERS (2021 V/S 2028) ($MN)
FIGURE 139 REST OF APAC MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPE & CONTRAST AGENTS BASED ON MOLECULE (2021) ($MN)
FIGURE 140 REST OF APAC CONTRAST AGENTS MARKET REVENUE, BASED ON MODALITY & ROUTE OF ADMINISTRATION (2021 V/S 2028) ($MN)
FIGURE 141 SOUTH KOREA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION (2021 V/S 2028) ($MN)
FIGURE 142 SOUTH KOREA MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING & END USERS (2021 V/S 2028) ($MN)
FIGURE 143 ROW MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON MOLECULE/ISOTOPE (2021 V/S 2028) (%)
FIGURE 144 ROW CONTRAST AGENTS MARKET SHARE, BASED ON MOLECULE (2021 V/S 2028) (%)
FIGURE 145 ROW NON-IONIC CONTRAST AGENTS MARKET SHARE, BASED ON CHEMICAL STRUCTURE (2021 V/S 2028) (%)
FIGURE 146 ROW MACROCYCLIC AGENTS MARKET SHARE, BASED ON IONICITY (2021 V/S 2028) (%)
FIGURE 147 ROW NUCLEAR IMAGING AGENTS MARKET SHARE, BASED ON ISOTOPE (2021 V/S 2028) (%)
FIGURE 148 ROW MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON MODALITY (2021 V/S 2028) (%)
FIGURE 149 ROW MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON APPLICATION (2021) (%)
FIGURE 150 ROW MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON ROUTE OF ADMINISTRATION (2021 V/S 2028) (%)
FIGURE 151 ROW MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON IMAGING (2021 V/S 2028) (%)
FIGURE 152 ROW MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON END-USER (2021 V/S 2028) (%)
FIGURE 153 ROW MEDICAL IMAGING AGENTS MARKET SHARE, BASED ON COUNTRY (2021 V/S 2028) (%)
FIGURE 154 TURKEY MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPE & CONTRAST AGENTS BASED ON MOLECULE (2021) ($MN)
FIGURE 155 TURKEY MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY AND ROUTE OF ADMINISTRATION (2021 V/S 2028) ($MN)
FIGURE 156 TURKEY MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION (2021 V/S 2028) ($MN)
FIGURE 157 TURKEY MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING AND END USERS (2021 V/S 2028) ($MN)
FIGURE 158 BRAZIL MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPE & CONTRAST AGENTS BASED ON MOLECULE (2021) ($MN)
FIGURE 159 BRAZIL MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY AND ROUTE OF ADMINISTRATION (2021 V/S 2028) ($MN)
FIGURE 160 BRAZIL MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION (2021 V/S 2028) ($MN)
FIGURE 161 BRAZIL MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING AND END USERS (2021 V/S 2028) ($MN)
FIGURE 162 OTHERS MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MOLECULE/ISOTOPE & CONTRAST AGENTS BASED ON MOLECULE (2021) ($MN)
FIGURE 163 OTHERS MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON MODALITY AND ROUTE OF ADMINISTRATION (2021 V/S 2028) ($MN)
FIGURE 164 OTHERS MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON APPLICATION (2021 V/S 2028) ($MN)
FIGURE 165 OTHERS MEDICAL IMAGING AGENTS MARKET REVENUE, BASED ON IMAGING AND END USERS (2021 V/S 2028) ($MN)
FIGURE 166 KEY GROWTH STRATEGIES (2020–2021)
FIGURE 167 SWOT: BAYER GROUP
FIGURE 168 SWOT: BRACCO GROUP
FIGURE 169 SWOT: CARDINAL HEALTH, INC
FIGURE 170 SWOT: CURIUM PHARMA
FIGURE 171 SWOT: FUJIFILM HOLDING CORPORATION
FIGURE 172 SWOT: GE HEALTHCARE
FIGURE 173 SWOT: GUERBET
FIGURE 174 SWOT: LANTHEUS MEDICAL IMAGING INC.
FIGURE 175 SWOT: NOVARTIS INTERNATIONAL AG
FIGURE 176 SWOT: SUMITOMO CHEMICALS
